

# Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death

Carlos Silvestre-Roig<sup>1,2,3,20\*</sup>, Quinte Braster<sup>1,2,3,20</sup>, Kanin Wichapong<sup>4</sup>, Ernest Y. Lee<sup>5</sup>, Jean Marie Teulon<sup>6</sup>, Nihel Berrebeh<sup>6</sup>, Janine Winter<sup>1</sup>, José M. Adrover<sup>7</sup>, Giancarlo Santiago Santos<sup>5</sup>, Alexander Froese<sup>8,9</sup>, Patricia Lemnitzer<sup>1</sup>, Almudena Ortega-Gómez<sup>1,3</sup>, Raphael Chevre<sup>1</sup>, Julian Marschner<sup>10</sup>, Ariane Schumski<sup>1,3</sup>, Carla Winter<sup>1,3</sup>, Laura Perez-Olivares<sup>1</sup>, Chang Pan<sup>1</sup>, Nicole Paulin<sup>1</sup>, Tom Schoufour<sup>2</sup>, Helene Hartwig<sup>1,2</sup>, Silvia González-Ramos<sup>1</sup>, Frits Kamp<sup>11</sup>, Remco T. A. Megens<sup>1,12</sup>, Kerri A. Mowen<sup>13,21</sup>, Matthias Gunzer<sup>14</sup>, Lars Maegdefessel<sup>3,15,16</sup>, Tilman Hackeng<sup>4</sup>, Esther Lutgens<sup>1,17</sup>, Mat Daemen<sup>2</sup>, Julia von Blume<sup>18</sup>, Hans-Joachim Anders<sup>10</sup>, Viacheslav O. Nikolaev<sup>8,9</sup>, Jean-Luc Pellequer<sup>6</sup>, Christian Weber<sup>1,3,4</sup>, Andrés Hidalgo<sup>1,7</sup>, Gerry A. F. Nicolaes<sup>4</sup>, Gerard C. L. Wong<sup>5</sup> & Oliver Soehnlein<sup>1,2,3,16,19\*</sup>


**The perpetuation of inflammation is an important pathophysiological contributor to the global medical burden. Chronic inflammation is promoted by non-programmed cell death<sup>1,2</sup>; however, how inflammation is instigated, its cellular and molecular mediators, and its therapeutic value are poorly defined. Here we use mouse models of atherosclerosis—a major underlying cause of mortality worldwide—to demonstrate that extracellular histone H4-mediated membrane lysis of smooth muscle cells (SMCs) triggers arterial tissue damage and inflammation. We show that activated lesional SMCs attract neutrophils, triggering the ejection of neutrophil extracellular traps that contain nuclear proteins. Among them, histone H4 binds to and lyses SMCs, leading to the destabilization of plaques; conversely, the neutralization of histone H4 prevents cell death of SMCs and stabilizes atherosclerotic lesions. Our data identify a form of cell death found at the core of chronic vascular disease that is instigated by leukocytes and can be targeted therapeutically.**

Neutrophils are readily available as part of the antimicrobial immune response and are irreplaceable during host defence, yet the same neutrophil-borne mediators can promote tissue injury and uphold inflammation. However, the mechanism by which neutrophils orchestrate collateral damage in nearby tissue is not well understood. Injury-triggered non-programmed cell death is a defining feature of chronic inflammation. Because excessive cell death is a hallmark of plaque destabilization, as exemplified by the importance of deceased SMCs<sup>3</sup>, here we studied the effect of lesional neutrophils on SMC survival. We generated advanced atherosclerotic lesions with features of instability in hypercholesterolemic mice<sup>4,5</sup> (Extended Data Fig. 1a–f). Lesional neutrophils inversely correlated with SMA<sup>+</sup> (smooth muscle actin) SMCs and fibrous cap thickness, while positively correlating with necrotic core area, lesion size and overall vulnerability (Fig. 1a–d, Extended Data Fig. 1g, h). Notably, no association was found between lesional neutrophils and collagen content (Extended Data Fig. 1i), lesional macrophages (Fig. 1b), endothelial cells and the activation status of macrophages and endothelial cells (Extended Data Fig. 1j–o). To establish causality between lesional neutrophil infiltration, SMC death and plaque stability, we induced sustained neutropenia by repeated injection of neutrophil-depleting antibodies or by genetic depletion of a neutrophil survival factor (*Apoe*<sup>−/−</sup>*Ly6g*<sup>cre</sup>*Mcl1*<sup>flox/flox</sup>). Alternatively, we generated systemic neutrophilia by pharmacological inhibition of CXCR4

or by deletion of *Cxcr4* in myeloid cells (*Apoe*<sup>−/−</sup>*Lyz2*<sup>cre</sup>*Cxcr4*<sup>flox/flox</sup>, Extended Data Fig. 2a). Neutropenia and neutrophilia diminished or enhanced, respectively, both circulating and lesional neutrophil counts (Extended Data Table 1, Extended Data Fig. 2b, c). Functionally, neutropenia increased SMC content and fibrous cap thickness—which resulted in lower overall plaque vulnerability—whereas the opposite was found in neutrophilic mice (Fig. 1e–h, Extended Data Fig. 2d–s). Alterations in the number of SMCs were associated with increased SMC death (Fig. 1i), but not with changes in cell proliferation (Extended Data Fig. 2t, u). Notably, human lesions that were infiltrated with higher numbers of neutrophils exhibited lower lesional SMC area and increased overall vulnerability (Extended Data Fig. 2v, w). Consistent with the observed neutrophil-based modulation of lesion-resident SMC numbers, intimal neutrophils were found in closer proximity to SMCs than were macrophages (Fig. 1j, k), which suggests a direct interaction between these two cell types.

Phenotypic transition of arterial SMCs towards a pro-inflammatory, secretory phenotype mediates leukocyte infiltration and atherosclerosis<sup>6</sup>. Because neutrophils predominantly located in proximity to lesional SMCs, we investigated whether activated SMCs guide neutrophils towards them. Supernatants obtained from platelet-derived growth factor-BB (PDGF-BB)-activated SMCs evoked chemotactic attraction (Fig. 2a, Extended Data Fig. 3a, b), followed by enhanced neutrophil–SMC interaction and neutrophil polarization (Fig. 2b). Because chemokine signalling is a prerequisite for neutrophil activation and neutrophil extracellular trap (NET) release (NETosis)<sup>7</sup>, we investigated whether secretory products of activated SMCs trigger neutrophils to undergo NETosis. Neutrophils incubated with the supernatant of PDGF-BB-treated SMCs produced increased amounts of reactive oxygen species and released NETs (Fig. 2c). These supernatants were enriched in the CCR2 ligands CCL2 and CCL7 (Fig. 2d, Extended Data Fig. 3c, d). Notably, only recombinant CCL7 evoked NET release (Fig. 2e). Furthermore, intimal CCL7 positively correlated with lesional NETs (Fig. 2f) but not with lesional neutrophil numbers (Extended Data Fig. 3e), and its blockade resulted in reduced numbers of intimal NETs (Fig. 2g). Consistent with the idea that activated SMCs promote NET release within the atherosclerotic lesion, NET-releasing neutrophils in mouse and human atherosclerotic lesions were predominantly found in the SMC-rich fibrous cap (Fig. 2h, i). This observation

<sup>1</sup>Institute for Cardiovascular Prevention (IPEK), LMU München, Munich, Germany. <sup>2</sup>Department of Pathology, AMC, Amsterdam, The Netherlands. <sup>3</sup>German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. <sup>4</sup>Department of Biochemistry, CARIM, University Maastricht, Maastricht, The Netherlands. <sup>5</sup>Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, USA. <sup>6</sup>Université Grenoble Alpes, CEA, CNRS, IBS, Grenoble, France. <sup>7</sup>Area of Developmental and Cell Biology, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain. <sup>8</sup>Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. <sup>9</sup>German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany. <sup>10</sup>Medizinische Klinik und Poliklinik IV, LMU München, Munich, Germany. <sup>11</sup>BMC, Metabolic Biochemistry, LMU München, Munich, Germany. <sup>12</sup>Department of Biomedical Engineering, CARIM, University Maastricht, Maastricht, The Netherlands. <sup>13</sup>The Scripps Research Institute, La Jolla, CA, USA. <sup>14</sup>Institute for Experimental Immunology and Imaging, University Hospital Essen, Essen, Germany. <sup>15</sup>Department of Vascular and Endovascular Surgery, Technical University Munich, Munich, Germany. <sup>16</sup>Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden. <sup>17</sup>Department of Medical Biochemistry, AMC, Amsterdam, The Netherlands. <sup>18</sup>Max Planck Institute of Biochemistry, Martinsried, Germany. <sup>19</sup>Department of Physiology and Pharmacology (FyFa), Karolinska Institutet, Stockholm, Sweden. <sup>20</sup>These authors contributed equally: Carlos Silvestre-Roig, Quinte Braster. <sup>21</sup>Deceased: Kerri A. Mowen. \*e-mail: oliver.sohnelein@gmail.com; carlos.silvestre@med.uni-muenchen.de



**Fig. 1 | Neutrophils dictate plaque stability.** **a–d**, Advanced lesions were generated by insertion of a shear stress modifier around the carotid artery. Pearson correlation between lesional neutrophils and SMC area ( $\text{SMA}^+$ , **a**), macrophage area ( $\text{CD68}^+$ , **b**), necrotic core area (**c**), and overall vulnerability (**d**).  $n = 28$  mice. Dotted line represents 95% confidence interval. **e–i**, Neutropenia (anti-Ly6G) or neutrophilia (AMD3100) were induced during the last 4 weeks of the experiment. Genetically neutropenic *Apoe*<sup>−/−</sup> mice (*Lyz6g*<sup>cre</sup>*Mcl1*<sup>fl/fl</sup>, *Mcl1*<sup>ΔN</sup>) were fed a high-fat diet for a total of 11 weeks and advanced atherosclerotic lesions were analysed in aortic roots. Genetic neutrophilia was established in *Apoe*<sup>−/−</sup> mice that were lethally irradiated and reconstituted with bone marrow from *Lyz2*<sup>cre</sup> mice or from *Lyz2*<sup>cre</sup>*Cxcr4*<sup>fl/fl</sup> (*Cxcr4*<sup>ΔN</sup>) mice. Antibody-induced neutropenic (anti-Ly6G,  $n = 10$  mice (**e–i**)), genetic neutropenic (*Mcl1*<sup>ΔN</sup>),  $n = 16$  mice (**e–h**),  $n = 10$  mice (**i**)), pharmacological neutrophilic (AMD3100,  $n = 15$  mice (**e–h**),  $n = 7$  mice (**i**)) and genetic neutrophilic (*Cxcr4*<sup>ΔN</sup>,  $n = 13$  mice (**e–h**),  $n = 11$  mice (**i**)) are compared with respective controls (isotype IgG,  $n = 10$  mice (**e–h**), *Ly6g*<sup>cre</sup>,  $n = 18$  mice (**e–h**),  $n = 10$


raised the question of whether intimal NETosis might exert cytotoxic effects that account for the inverse relationship between the numbers of lesional neutrophils and SMCs. Consistent with this, intimal NETs in mouse (Fig. 2j) and human (Fig. 2k) atherosclerotic lesions inversely correlated with SMC content and resided in close proximity to dead SMCs (Extended Data Fig. 3f, g). Notably, such trap–DNA structures were found to be primarily of neutrophil origin (Extended Data Fig. 3h–j). To investigate the cytotoxic effect of NETs on SMCs, SMCs were incubated with phorbol myristate acetate (PMA)- or CCL7-induced NETs (Extended Data Fig. 3k, l), which resulted in reduced cell viability. Pharmacological (Cl-amidine treatment) or genetic (mice that lacked *Pad4*) blockade of NET release resulted in increased lesional SMC content and decreased overall plaque vulnerability (Fig. 2l–n, Extended Data Fig. 4, Extended Data Table 1).

NETs are decorated with granule-derived and nuclear proteins that determine their functionality<sup>8</sup>. Antibody- and inhibitor-based blocking of abundant NET-resident granule proteins did not affect NET-evoked cytotoxicity (Extended Data Fig. 5a, b), whereas the neutralization of histone H2A and H4 significantly rescued SMC viability (Fig. 3a). Notably, NET structures disrupted by DNase treatment retained cytotoxicity capacity. However, under these conditions, the neutralization of H2A failed to block NET-mediated cytotoxicity, whereas the effect of histone H4 blockade was preserved (Fig. 3a). In addition, recombinant histone H4 potently induced cell death (Fig. 3b), which suggests that NET-bound and free histone H4 exhibit strong cytotoxicity (Extended Data Fig. 5c). As histone H4 was abundant in intimal NETs (Extended Data Fig. 5d) and because extranuclear histone H4 positively correlated with the number of intimal neutrophils (Fig. 3c, Extended Data Fig. 5e), we investigated the effect of histone H4 on the destabilization of atherosclerotic plaques. Antibody blockade of histone H4 in hypercholesterolemic mice with established lesions generated plaques with reduced vulnerability and increased lesional SMC content (Fig. 3d–f, Extended Data Fig. 6, Extended Data Table 1).

mice (**i**), vehicle ( $n = 15$  mice (**e–h**),  $n = 7$  mice (**i**)), or *Lyz2*<sup>cre</sup> ( $n = 11$  mice (**e–h**),  $n = 9$  mice (**i**))), respectively, dashed line. Displayed is the quantification of the SMC ( $\text{SMA}^+$ ) area (**e**), macrophage area ( $\text{CD68}^+$ , **f**), necrotic core area (**g**), and overall vulnerability (**h**). **i**, Dead SMCs were quantified as TUNEL<sup>+</sup> $\text{SMA}^+$  cells. For the AMD3100 condition, a two-sided Mann–Whitney test was used. **j**, Representative immunofluorescence micrograph showing lesional neutrophils (Ly6G<sup>+</sup>, grey), SMCs ( $\text{SMA}^+$ , red), macrophages ( $\text{CD68}^+$ , magenta) and nuclei (DAPI, blue). Dotted lines indicate cross-section views. The diagonal cross-section is shown at the top (xyz) and the vertical cross-section is shown on the right (yz). Intensity profiles of the indicated emission wavelengths are shown. **k**, Violin plot showing the distance of intimal neutrophils to macrophages ( $\text{CD68}^+$ ) ( $n = 148$  cells) and SMCs ( $\text{SMA}^+$ ) ( $n = 171$  cells). The median is represented by the horizontal line within the white box, and the boundaries of the box indicate the interquartile range. Two-sided unpaired *t*-tests were used unless otherwise stated; \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ . Data are mean  $\pm$  s.d.

NET-derived histones can induce endothelial cell cytotoxicity through the activation of Toll-like receptors (TLRs)<sup>9</sup>. However, inhibition of TLR signalling did not affect NET-mediated SMC death (Extended Data Fig. 7a). Instead, histone H4 induced the ultra-rapid release of cytoplasmic calcine and uptake of propidium iodide in SMCs (Fig. 3g, h, Supplementary Video 1) and whole-mount atherosclerotic lesions (Fig. 3i), suggesting a non-programmed cell-death process. Guided by previous reports that suggested the membrane activity of histone H4 in bacteria<sup>10</sup>, we proposed that histone H4 interacts with the SMC plasma membrane to induce cell lysis. High-resolution imaging of SMCs with either NETting neutrophils (Fig. 3j, Extended Data Fig. 7b) or recombinant histone H4 (Fig. 3k, Extended Data Fig. 7c, Supplementary Video 2) revealed a direct interaction of histone H4 with the plasma membrane, a finding that was corroborated by biotin-assisted pull-down of membrane-bound proteins of SMCs (Fig. 3l). In accordance with a cell lysis mechanism, NETs or histone H4 induced SMC swelling and the release of ATP (Extended Data Fig. 7d–g). Given the cationic properties of histone H4 ( $\zeta$  potential  $26.64 \pm 2.82$  mV) and the anionic nature of the plasma membrane, we tested whether histone H4–membrane interaction was mediated by electrostatic forces. Manipulation of the SMC surface charge using oleylamine or cholesterol sulfate increased or decreased cationicity, respectively (Extended Data Fig. 7h), thus inhibiting or promoting histone H4–membrane anchorage (Extended Data Fig. 7i) and consequent cell death (Extended Data Fig. 7j).

The apparent disruption of the integrity of the SMC plasma membrane and the rapid induction of death by histone H4 prompted us to investigate the biophysical basis of histone H4-mediated membrane permeation. Atomic force microscopy on artificially reconstituted membrane bilayers incubated with histone H4 showed the appearance of pores (Fig. 4a). Similarly, when SMCs were exposed to histone H4, alterations in the membrane were observed (Extended Data Fig. 8a) as a result of dynamic bending and pore formation (Fig. 4b).



**Fig. 2 | Activated smooth muscle cells trigger NETosis promoting atherosclerotic plaque vulnerability.** **a**, Tracks (left) and speed (right) of neutrophil migration towards the supernatant of PDGF-BB-activated SMCs.  $n = 20$  ctrl;  $n = 19$  PDGF-BB neutrophils. \* $P = 0.00001$ . **b**, Number of adherent neutrophils to SMCs (Ly6G, green;  $n = 39$  ctrl,  $n = 35$  PDGF-BB) and their CD62L polarization frequency (red;  $n = 26$  ctrl,  $n = 28$  PDGF-BB). Scale bar, 50  $\mu$ m. \* $P = 0.0002$ ; \*\* $P = 0.009$ . **c**, Reactive oxygen species (ROS) production (left,  $n = 9$  ctrl;  $n = 10$  PDGF-BB) and NET release (right,  $n = 22$  ctrl;  $n = 25$  PDGF-BB) of neutrophils exposed to supernatants of resting (ctrl) or PDGF-BB-activated SMCs. \* $P = 0.004$ ; \*\* $P = 0.008$ . **d**, CCL2 and CCL7 levels in supernatants from PDGF-BB-activated SMCs.  $n = 10$ . Two-sided paired *t*-test. **e**, NET release by VCAM-1-bound neutrophils treated with vehicle, CCL2 or CCL7, compared to non-coated control.  $n = 10$  fields. One-way ANOVA with Holm–Sidak correction. **f**, Pearson correlation between NETs and intimal CCL7 in advanced atherosclerotic lesions in mice.  $n = 28$  sections. **g**, *Apoe*<sup>-/-</sup> mice with advanced atherosclerotic lesions were treated with anti-CCL7 or isotype IgG and lesional NETs were quantified. Representative micrographs are shown. Ly6G, magenta;

A machine-learning classifier that was trained to identify  $\alpha$ -helical membrane-active sequences<sup>11</sup> revealed high  $\sigma$  scores within the histone H4 N terminus (Extended Data Fig. 8b). Such scores correlate with the ability to generate negative Gaussian curvature in membranes required for pore formation, as shown for cell-penetrating polypeptides<sup>12,13</sup>. To validate this prediction we performed small-angle X-ray scattering on small unilamellar vesicles incubated with the histone H4 N terminus, and observed strong, dose-dependent membrane deformation rich in negative Gaussian curvature (*Pn3m* cubic phases). Gaussian curvature ( $\langle K \rangle$ ) values were comparable to those obtained from other membrane-remodelling proteins<sup>12</sup>; such remodelling is facilitated in cholesterol-containing membranes (Fig. 4c, Extended Data Fig. 8c). Consistent with this, the histone H4 N terminus interacted with SMC membranes (Extended Data Fig. 8d) and induced cell death (Extended Data Fig. 8e).


Owing to the importance of SMC death in the regulation of plaque vulnerability, we explored therapeutic strategies to prevent histone H4-driven cytotoxicity. Molecular dynamic simulation of histone H4 in the presence of membrane structures confirmed that the N-terminal region is responsible for the H4–membrane interaction (Fig. 5a). Consequently, we screened for peptides that were predicted to form stable complexes with the H4 N terminus. The cyclical peptide HIPe (histone inhibitory peptide) showed a potential ability to efficiently disturb histone H4–membrane interactions (Fig. 5a). Consistent with this prediction, HIPe prevented histone H4 from interacting with

citrullinated histone H3, green; DNA (DAPI), blue. Dashed line delineates intima. Scale bar, 100  $\mu$ m.  $n = 44$  sections IgG;  $n = 27$  sections anti-CCL7. **h**, **i**, Percentage of NETting neutrophils present in the indicated compartments of mouse (**h**) or human (**i**) atherosclerotic lesions.  $n = 33$  sections in **h** and  $n = 13$  core and  $n = 16$  cap in **i**. **j**, **k**, Pearson correlation between NETs and SMC (SMA<sup>+</sup>) area in mouse (**j**,  $n = 57$  mice) and human (**k**,  $n = 38$  sections) atherosclerotic lesions. **l–n**, Advanced lesions were generated by insertion of a shear stress modifier around the carotid artery. Pharmacologic (Cl-amidine, Cl-a, during last 4 weeks,  $n = 9$  mice) or genetic (*Apoe*<sup>-/-</sup>/*Pad4*<sup>-/-</sup>,  $n = 8$  mice) inhibition of NET release and respective controls (PBS treatment,  $n = 8$  mice, or *Apoe*<sup>-/-</sup>/*Pad4*<sup>+/+</sup>,  $n = 6$  mice). Representative immunostaining images (**l**) show SMC (SMA, red) and nuclei (DAPI, blue). The dotted line delineates SMCs from the necrotic core, the dashed line outlines the lumen. Scale bar, 50  $\mu$ m. Quantification of SMC area (SMA<sup>+</sup>, **m**) and vulnerable plaque index (**n**). Tested against respective control. \* $P < 0.05$ . All data are presented as mean (red line)  $\pm$  s.d. L, lumen; NC, necrotic core; SPN, supernatant. Dotted lines in **f**, **j** and **k** represent 95% confidence interval. Two-sided unpaired *t*-test;  $n$  indicates biological samples unless otherwise stated.

(Extended Data Fig. 8f) and altering (Extended Data Fig. 8g, h) membranes, and from inducing SMC death (Extended Data Fig. 8i). We next investigated the therapeutic benefits of HIPe on atherosclerotic plaque vulnerability. The continuous administration of HIPe to mice with pre-existing atherosclerotic lesions resulted in increased lesional SMC content, and generated lesions with increased stability traits both in carotid (Fig. 5b–d, Extended Data Fig. 9a–q, Extended Data Table 1) and brachiocephalic (Extended Data Fig. 9r–x) lesions without altering neutrophil recruitment (Extended Data Fig. 9y, z).

The identification of new therapeutic strategies to inhibit cell death associated with chronic inflammation, as exemplified by cardiovascular diseases, is a major challenge in modern medicine. Here we identify a form of histone-induced death as a source of chronic inflammation within arterial walls that increases instability traits in atherosclerotic plaques. Histone H4 is released from neutrophils which are attracted and rendered prone to releasing histone-containing NETs by SMCs (Extended Data Fig. 9aa, Supplementary Video 3).

Upon danger, neutrophils rapidly infiltrate the inflammatory site and cause severe tissue injury as a collateral effect of their function. At the vascular site, rapid release of cytotoxic NETs exerts severe tissue damage, thereby reducing structural signs of stability of the atherosclerotic plaque. Luminal<sup>14</sup> or abluminal deposition of NET-derived products may lead to death of endothelial cells or SMCs, respectively, and hence dictate diverse aetiologies of cardiovascular pathologies.




**Fig. 3 | NET-derived histone H4 induces SMC lysis and exacerbates plaque instability.** **a**, SMCs were treated with NETs pre-incubated with antibodies to histone isoforms and cell death was measured as propidium iodide positive ( $\text{PI}^+$ ) cells.  $n = 57$  IgG;  $n = 58$  anti-H2A;  $n = 59$  anti-H3;  $n = 58$  anti-H4 fields. One-way ANOVA with Tukey's correction;  $*P = 0.014$ ;  $**P = 0.007$ . Where indicated, NETs were treated with DNase before incubation with indicated antibodies.  $n = 24$  fields. Two-sided unpaired  $t$ -test;  $*P = 0.044$ ;  $**P = 0.007$ . **b**, Histone H4-induced SMC death quantified by PI uptake.  $n = 24$  fields. Two-sided unpaired  $t$ -test,  $*P = 1.27 \times 10^{-9}$ . **c**, Pearson correlation between extracellular histone H4 and neutrophils in intimas.  $n = 20$  mice. Dotted line represents 95% confidence interval. **d–f**,  $\text{Apoe}^{-/-}$  mice with advanced lesions were treated with isotype IgG ( $n = 14$  mice) or anti-histone H4 ( $n = 15$  mice) during the last 4 weeks of the experiment. **d**, Representative immunostaining for SMCs (SMA, red) and nuclei (DAPI, blue). The dotted line delineates SMCs from the necrotic core, the dashed line outlines the lumen. Scale bar, 50  $\mu\text{m}$ . **e**, **f**, Quantification of SMC area (SMA $^+$ , **e**) and plaque vulnerability (**f**). Two-sided unpaired  $t$ -test.  $*P = 0.0009$ . **g**, **h**, Time-lapse microscopy of SMCs treated with histone H4 showing PI entry and calcine dispersion. **g**, Representative micrographs. Scale bar, 10  $\mu\text{m}$ . **h**, Quantification over time.  $n = 15$  cells. **i**, Time-lapse two-photon microscopy of whole-mount lesions stained with calcine (green) and anti-CD31 (blue) recorded in the presence of PI and histone H4. Scale bar, 100  $\mu\text{m}$ . **j**, **k**, Visualization of cell membrane (lectin, white), histone H4 (magenta) and DNA (DAPI, cyan) in a SMC (S) and neutrophil co-culture (**j**) or in SMCs treated with recombinant histone H4 (**k**). White arrows indicate NET-derived histone H4 SMC plasma membrane interactions. **l**, SMCs treated with recombinant histone H4 were labelled with sulfo-NHS-SS-biotin. Western blot of non-purified lysates (SMCs) and plasma membrane fractions (SMCs avidin-purified) with indicated antibodies (for gel source data, see Supplementary Fig. 1). Data are mean  $\pm$  s.d.


cells induce rapid, receptor-independent cell death in SMCs via the formation of membrane pores, thus contributing to vascular tissue damage. Owing to the controversial antimicrobial effector function of NETs<sup>17</sup>, peptide-based histone H4 blockade could have potential as a

As well as the architectural function of histones in chromatin organization, histones released upon cell damage are noxious and induce tissue damage<sup>15,16</sup>. Our data indicate that histones—and in particular histone H4—that originate from intimal NETs and possibly necrotic

vesicles, with membrane compositions as indicated at increasing peptide:lipid ratios. The peptide induced  $Pn3m$  cubic phases, which are rich in NGC, and are indicative of membrane permeation. The plot shows the absolute value of NGC induced by histone H4 N terminus as a function of the protein:lipid charge ratio. Chol, cholesterol; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOPS, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine.



**Fig. 4 | Membrane-pore-forming activity of histone H4.** **a**, Atomic force microscopy images of reconstituted membrane lipid bilayers incubated with recombinant histone H4. Scale bar, 1  $\mu\text{m}$ . **b**, Live scanning ion conductance microscopy of SMCs. Images represent the plasma membrane before (top) and after (bottom) incubation with histone H4. **c**, Small angle X-ray scattering data demonstrate that the N-terminal domain of histone H4 induces negative Gaussian curvature (NGC) in small unilamellar



**Fig. 5 | Therapeutic disruption of the histone H4–plasma membrane interaction stabilizes atherosclerotic lesions.** **a**, Molecular dynamics simulations of the interaction between histone H4 (magenta) and the plasma membrane. The N-terminal domain of histone H4 (cyan) exhibits membrane activity (left). Histone inhibitory peptide (Hipe, green) binds to the N terminus of histone H4 (middle) and disrupts the interaction with the cell membrane (right). **b–d**, Hypercholesterolemic mice with established atherosclerotic lesions were implanted with osmotic

therapeutic strategy for the prevention of damage to vascular as well as other types of tissue, without substantially compromising NETosis-mediated host defence.

## Online content

Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at <https://doi.org/10.1038/s41586-019-1167-6>.

Received: 28 November 2017; Accepted: 2 April 2019;

Published online 1 May 2019.

- Kolb, J. P., Oguin, T. H., III, Oberst, A. & Martinez, J. Programmed cell death and inflammation: winter is coming. *Trends Immunol.* **38**, 705–718 (2017).
- Tabas, I. Macrophage death and defective inflammation resolution in atherosclerosis. *Nat. Rev. Immunol.* **10**, 36–46 (2010).
- Clarke, M. C. H. et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. *Nat. Med.* **12**, 1075–1080 (2006).
- Hartwig, H. et al. Atherosclerotic plaque destabilization in mice: a comparative study. *PLoS ONE* **10**, e0141019 (2015).
- Silvestre-Roig, C. et al. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. *Circ. Res.* **114**, 214–226 (2014).
- Bennett, M. R., Sinha, S. & Owens, G. K. Vascular smooth muscle cells in atherosclerosis. *Circ. Res.* **118**, 692–702 (2016).
- Rossant, J. et al. Synchronized integrin engagement and chemokine activation is crucial in neutrophil extracellular trap-mediated sterile inflammation. *Blood* **123**, 2573–2584 (2014).
- Papayannopoulos, V. Neutrophil extracellular traps in immunity and disease. *Nat. Rev. Immunol.* **18**, 134–147 (2018).
- Kumar, S. V. et al. Neutrophil extracellular trap-related extracellular histones cause vascular necrosis in severe GN. *J. Am. Soc. Nephrol.* **26**, 2399–2413 (2015).
- Tagai, C., Morita, S., Shiraishi, T., Miyaji, K. & Iwamuro, S. Antimicrobial properties of arginine- and lysine-rich histones and involvement of bacterial outer membrane protease T in their differential mode of actions. *Peptides* **32**, 2003–2009 (2011).
- Lee, E. Y., Fulan, B. M., Wong, G. C. & Ferguson, A. L. Mapping membrane activity in undiscovered peptide sequence space using machine learning. *Proc. Natl. Acad. Sci. USA* **113**, 13588–13593 (2016).
- Schmidt, N. W. et al. Criterion for amino acid composition of defensins and antimicrobial peptides based on geometry of membrane destabilization. *J. Am. Chem. Soc.* **133**, 6720–6727 (2011).
- Schmidt, N. W. & Wong, G. C. Antimicrobial peptides and induced membrane curvature: geometry, coordination chemistry, and molecular engineering. *Curr. Opin. Solid State Mater. Sci.* **17**, 151–163 (2013).
- Franck, G. et al. Roles of PAD4 and NETosis in experimental atherosclerosis and arterial injury: implications for superficial erosion. *Circ. Res.* **123**, 33–42 (2018).
- Saffarzadeh, M. et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. *PLoS ONE* **7**, e32366 (2012).
- Xu, J. et al. Extracellular histones are major mediators of death in sepsis. *Nat. Med.* **15**, 1318–1321 (2009).

minipumps delivering vehicle or Hipe for the last four weeks of the experiment. **b**, Representative immunostaining images for SMC (SMA, red) and nuclei (DAPI, blue) of atherosclerotic lesions. The dotted line delineates SMCs from the necrotic core, the dashed line outlines the lumen. Scale bar, 50  $\mu$ m. **c**, **d**, Quantification of SMC area ( $SMA^+$ , **c**) and overall lesion vulnerability (**d**). Two-sided unpaired *t*-test, *n* = 12 mice (vehicle) or *n* = 11 mice (Hipe).

- Menegazzi, R., Decleva, E. & Dri, P. Killing by neutrophil extracellular traps: fact or folklore? *Blood* **119**, 1214–1216 (2012).

**Acknowledgements** The study was supported by the DFG (SFB914 TP B8, SFB1123 TP A6, B5, Z1, S0876/6-1, S0876/11-1, AN372/14-3, AN372/24-1, INST409/97-1FUGG and INST409/150-1FUGG), the EKFS (2016\_A118, 2017\_A13), the NWO (VIDI project 91712303), the Leducq foundation, and the Vetenskapsrådet. Funding was also provided by grants SAF2015-65607-R to A.H., BES-2013-065550 to J.M.A., and Severo Ochoa Center of Excellence (award SEV-2015-0505) to CNIC, all from the Ministerio de Ciencia, Innovación y Universidades. We thank O. Schengel for mouse genotyping and V. Lavilla for generating video animations. This work used the platforms of the Grenoble Instruct-ERIC Center (ISBG: UMS 3518 CNRS-CEA-UGA-EMBL) with support from FRISBI (ANR-10 INSB-05-02) and GRAL (ANR-10-LABX-49-01). E.Y.L. acknowledges support from the Systems and Integrative Biology Training Program (T32GM008185), the Medical Scientist Training Program (T32GM008042), and the Dermatology Scientist Training Program (T32AR071307) at UCLA. E.Y.L. and G.C.L.W. acknowledge an Early Career Research Grant and a Discovery Grant, respectively, from the National Psoriasis Foundation. G.C.L.W. also acknowledges support from NIH R56AI125429-01A1.

**Reviewer information** *Nature* thanks Peter Libby and the other anonymous reviewer(s) for their contribution to the peer review of this work.

**Author contributions** C.S.-R. and Q.B. designed and performed experiments, analysed data, interpreted data and wrote the manuscript. K.W., E.Y.L., J.M.T., N.B., J.W., J.M.A., G.S.S., A.F., A.O.-G., J.M., P.L., R.C., A.S., C. Winter, L.P.-O., C.P., T.S., H.H., J.v.B. and S.G.-R. contributed to data acquisition and analysis; N.P. supervised animal experimentation; F.K., R.T.A.M., H.-J.A., V.O.N., A.H., J.-L.P., G.C.L.W. and G.A.F.N. supervised specific data acquisition and analysis and provided funding; C. Weber provided scientific infrastructure, access to *Lyz2cre/Cxcr4fl/fl* mice, and contributed to the funding of K.W.; K.A.M. provided *Pad4* mice; M.G. provided *Ly6gcre* mice; T.H. synthesized peptides; and L.M., E.L. and M.D. provided human samples and contributed to data analyses. O.S. conceived and supervised the study, designed experiments and interpreted data, provided funding and wrote the paper. A.H., G.C.L.W. and G.A.F.N. contributed equally to this study.

**Competing interests** The authors declare no competing interests.

## Additional information

**Extended data** is available for this paper at <https://doi.org/10.1038/s41586-019-1167-6>.

**Supplementary information** is available for this paper at <https://doi.org/10.1038/s41586-019-1167-6>.

**Reprints and permissions information** is available at <http://www.nature.com/reprints>.

**Correspondence and requests for materials** should be addressed to O.S. or C.S.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## METHODS

**Ethics statement.** All mouse experiments were performed according to European guidelines for the Care and Use of Laboratory Animals. Protocols were approved by the Committee on the Ethics of Animal Experiments of the Academic Medical Center (DBC102939), Amsterdam and Regierung von Oberbayern (55.2-1-54-2532-159-2014).

**Mouse procedures.** For mouse experiments, statistical power calculations were performed as described at <http://www.stat.uiowa.edu/~rlenth/Power/> to determine sample size. Mice were assigned to groups randomly and data collection and analysis were performed blinded. Mice were housed according to institutional regulations with ad libitum access to food and water. All mice used were females in the C57BL/6 background. Apolipoprotein E-deficient mice (*Apoe*<sup>-/-</sup>) were purchased from The Jackson Laboratory. *Ly6g*<sup>cre</sup> mice (ref.<sup>18</sup>) (obtained from M.G., Institute for Experimental Immunology and Imaging, University Hospital, University Duisburg-Essen) were intercrossed with *Apoe*<sup>-/-</sup> and *Mcl1*<sup>flox/flox</sup> mice (ref.<sup>18</sup>) (obtained from Y.-W. He, Department of Immunology, Duke University Medical Center) to generate triple-mutant mice. *Pad4*<sup>-/-</sup> mice (obtained from K.A.M., The Scripps Research Institute) were intercrossed with *Apoe*<sup>-/-</sup> mice to generate double-mutant mice. *Apoe*<sup>-/-</sup> recipient mice were lethally irradiated and reconstituted with bone marrow obtained from *Apoe*<sup>-/-</sup> *Lyz2*<sup>re</sup>*Cxcr4*<sup>flox/flox</sup> mice or *Apoe*<sup>-/-</sup> mice to generate mouse chimaeras. Vulnerable atherosclerotic lesions were induced as described in ref.<sup>4</sup>. In brief, eight-week-old mice were fed a high-fat diet (HFD; 21% fat and 0.15% cholesterol) for 11 weeks. Two weeks after the initiation of the HFD, a cast was placed around the left common carotid artery. To induce neutropenia, mice received anti-Ly6G (clone 1A8) or control IgG (2A3, 50 µg, every other day, BioXcell) intraperitoneally (i.p.). Neutrophilia was induced by daily subcutaneous injection of AMD3100 (5 mg kg<sup>-1</sup>, Tocris) or PBS as control. Pharmacological inhibition of NET release was performed by daily subcutaneous administration of Cl-amidine (10 mg kg<sup>-1</sup>, Essen Scientific). To block histone H4, mice were treated with intraperitoneal injection of anti-histone H4 (20 µg per day, Biorbyt, orb225483) or control IgG (Dianova). Administration of peptide HIPe or scrambled HIPe (sHIPe) was performed by using osmotic minipumps (4 mg per kg per day, Alzet, model 2004). All treatments were performed during the last 4 weeks of the experiment to therapeutically treat pre-established atherosclerotic plaques. For the model of spontaneous atheroprogresion, *Apoe*<sup>-/-</sup> mice were fed a HFD for 16 weeks. For in vivo blockade of CCL7, 18–24 week-old *Apoe*<sup>-/-</sup> mice were injected with anti-CCL7 or isotype IgG (5 µg i.p., 3 times) over the last two days before euthanasia. To assess the effect of HIPe on neutrophil recruitment and mobilization, mice receiving either vehicle control or HIPe (100 µg, i.v.) were subjected to peritonitis by administration of TNF (100 ng, i.p., 4 h). Neutrophil counts in peritoneal lavage, bone marrow and blood were quantified by flow cytometry.

**Human carotid endarterectomy specimens.** Carotid endarterectomy (CEA) specimens were obtained from the vascular surgery department of the Academic Medical Center in Amsterdam. Immediately after removal, specimens were transferred to the Department of Pathology, fixed in 10% formalin and processed for paraffin embedding. Carotid atherosclerotic plaques were collected from all carotid endarterectomy surgeries performed at the Academic Medical Center in Amsterdam between 2008 and 2010. Specimens were collected according to the Code for Proper Secondary Use of Human Tissue in the Netherlands. This means that all personal information on age, use of medication, all underlying diseases is not available, and can indeed cause a potential bias. Informed consent as well as ethical approval are not required, as this is considered 'waste material' and can be used for science according to the Code for Proper Secondary Use of Human Tissue in the Netherlands.

**Tissue processing.** Mice were euthanized by ketamine/xylazine overdose, the blood was collected by heart puncture after which the mice were flushed with 20 ml of ice-cold PBS-EDTA (5 mM EDTA). Subsequently, the left common carotid artery was embedded in Tissue Tek O.C.T. compound (Sakura Finetek) for analysis. Aortic arches and hearts were isolated, fixed with 4% PFA and embedded in paraffin and in Tissue Tek O.C.T. compound (Sakura Finetek), respectively.

**Flow cytometry.** Blood was incubated with red blood cell lysis buffer (150 mM NH<sub>4</sub>Cl, 10 mM KHCO<sub>3</sub>, 0.1 mM Na<sub>2</sub>EDTA) for 5 min at room temperature. Leukocytes were stained with antibodies to CD45 (BioLegend, clone: 30-F11), CD11b (BioLegend, clone: M1/70), Ly6G (BioLegend, clone: 1A8), Ly6C (BioLegend, clone: Hk1.4), CD115 (eBioscience, clone: AFS98), Ly6B.2 (BIORAD, clone: 7/4) in staining buffer (20 min, 4°C). Flow cytometry was performed using the LSR Fortessa (Beckton Dickinson) and data was analysed using FlowJo software (Beckton Dickinson). Haematologic counts were determined with the ScilVet ABC Plus analyser (scil animal care company GmbH).

**Histology and immunofluorescence.** Carotid (7 µm) and aortic root (4 µm) cryosections or aortic arch paraffin sections (4 µm) were histologically stained with haematoxylin and eosin (H&E) in 70, 40, or 40 µm intervals, respectively. Total collagen content was assessed by Picosirius Red staining in consecutive sections. For immunofluorescence staining, cryosections were fixed with cold

acetone followed by antigen blockade using 5% goat serum/phosphate buffered saline. Paraffin sections underwent antigen retrieval with citrate buffer (10 mM, pH 6.0) before antigen blockade using 5% goat serum/phosphate buffered saline. Next, sections were incubated overnight at 4 °C with the following primary antibodies: rabbit anti-mouse CD68 (Abcam, 1:200), rat anti-mouse Ly6G (BD, 1:200), mouse anti-mouse smooth muscle actin (SMA)-FITC or -Cy3 conjugated (Sigma, 1:500), rabbit anti-mouse histone H4 (Abcam, 1:200), rabbit anti-mouse histone H4 Alexa 488 conjugated (Abcam, 1:200), rabbit anti-mouse citrullinated histone H3 (Abcam, 1:200), rat anti-mouse CD31-Alexa 455 conjugated (BioLegend, 1:50), rat anti-mouse VCAM-1 (R&D, 1:100), Armenian hamster anti-mouse ICAM-1 (BD Biosciences, 1:100), rabbit anti-iNOS (Abcam, 1:200), rat anti-mouse CD206-Fitc conjugated (BioLegend, 1:50), rabbit anti-mouse Ki67 (Thermo Fisher, 1:100), rabbit anti-mouse smooth muscle myosin heavy chain 11 (Abcam, 1:200), rabbit anti-mouse CCL7 (Biorbyt, 1:100). After extensive washing, sections were incubated with secondary antibodies conjugated with DyLight 488, DyLight 550 or DyLight 650 (Thermo Fisher, 1:500). Counterstain to visualize nuclei was performed by incubating with DAPI (Molecular Probes). Cell death (TUNEL<sup>+</sup> cells) was detected using ApopTag Red in situ Apoptosis Detection Kit (Millipore) following the manufacturer's instructions. For staining of plasma membranes, cells were incubated with Cytopainter Phalloidin Fluor 647 (Abcam, 1:1,000) or lectin-FITC conjugated (*Triticum vulgaris*, Sigma-Aldrich, 1:1,000). Biotinylated fragments of histone H4 were detected using streptavidin-PE (BioLegend, 1:100). Immunofluorescence sections were imaged using a Leica TCS SP8 (Leica Microsystems) equipped with a UV laser, a freely tunable, pulsed white light laser, hybrid detectors and a 63X1.40 oil objective. Raw pictures were deconvolved with Huygens Professional (v.16.10, Scientific Volume Imaging) and maximum intensity projections of deconvolved data were generated with the Leica Application Suite X (v.3.1 Leica Microsystems). Histological sections were quantified by computer-assisted morphometric analysis using ImageJ software (National Institutes of Health).

For human samples, plaque size and necrotic core area were quantified in 4 µm paraffin sections stained with H&E. Consecutive sections were used for histological analysis of neutrophils, neutrophil extracellular traps (NETs) and smooth muscle cells (SMCs). First, antigen retrieval was performed with Laboratory Vision citrate buffer (Thermo Fisher) and sections were blocked using Laboratory Vision Ultra V-Block (Thermo Fisher). Next, sections were incubated with antibodies against CD177 (Abnova, 1:2,000), citrullinated histone H3 (1:4,000) and smooth muscle actin (1:200), followed by secondary antibodies conjugated with alkaline phosphatase (Immunologic, 1:100) or poly-horseradish peroxidase (Southern Biotech, 1:100). Staining was developed by diaminobenzidine and Vector Blue substrate (Vector Laboratories), and counter-stained with nuclear red. Images were acquired by Philips Scanner (Philips).

To analyse extranuclear histone H4, we performed staining of nuclei (DAPI) and histone H4. Original pictures were converted into binary images (nuclei and histone H4) using ImageJ software. To obtain extranuclear histone H4, the signal from the nucleus was subtracted from the signal from histone H4.

**Murine and human plaque analysis.** Plaque vulnerability was assessed as described in ref.<sup>4</sup> (Extended Data Fig. 1a-f). In brief, intima, media and necrotic core area was analysed in H&E-stained sections. To assess lesion volumes, lesion area of sections was measured every 70 µm. To calculate the lesion volume, the volume of a cylinder with a different radius was calculated as:

$$\sum_{i=1}^n \frac{1}{3} \times \pi \times h \left( \sqrt{\frac{\text{Intima area}(n)}{\pi}} \right)^2 + \left( \sqrt{\frac{\text{Intima area}(n)}{\pi}} \times \sqrt{\frac{\text{Intima area}(n+1)}{\pi}} \right) + \left( \sqrt{\frac{\text{Intima area}(n+1)}{\pi}} \right)^2 \right)$$

where *h* is the distance between quantified sections of a mouse and *n* is the number of quantified sections.

The necrotic core (NC) was defined as the area devoid of nuclei underneath a formed fibrous cap. Collagen content and fibrous cap thickness were measured on Picosirius Red-stained sections. Fibrous cap (FC) thickness was defined as the average of length measurements in the positions overlapping with the lines of a square-shaped grid. For atherosclerotic lesions from the carotid artery but not from the brachiocephalic artery or the aortic root, averaged FC were corrected by intima size. Vulnerability Plaque Index (VPI) was calculated as VPI = (% NC area + % CD68 area) / (% SMA area + % collagen area). Mice with carotid samples showing absence of lesion formation were excluded from this analysis. To process and analyse SMA<sup>+</sup>MYH11<sup>+</sup>CD68<sup>-</sup>, SMA<sup>-</sup>MYH11<sup>+</sup>CD68<sup>-</sup> and CD68<sup>+</sup>MYH11<sup>-</sup>SMA<sup>-</sup> cells,

immunofluorescence pictures for SMA, MYH11 and CD68 were segmented by thresholding to create binary images. Binary images were mathematically combined to create cell masks of identified cell populations: SMA<sup>+</sup> MYH11<sup>+</sup>CD68<sup>-</sup>, cell mask was created by subtracting CD68 signal from SMA-MYH11 co-localized area; SMA<sup>-</sup>MYH11<sup>+</sup>CD68<sup>-</sup> cell mask was created by subtracting SMA and CD68 signal from MYH11 and CD68<sup>+</sup>MYH11<sup>-</sup>SMA<sup>-</sup> cell mask was created by subtracting SMA and MYH11 signal from CD68 area. NETs were identified by combination of antibodies to Ly6G and CitH3 as well as by DAPI staining. Where stated, MPO and histone H4 were used as complementary markers (see Fig. 2g, Extended Data Figs. 3h, 5d).

For human atherosclerosis, H&E stained sections were scored blinded by two independent, experienced pathologists with little inter- and intra-observer variability. Plaques were classified as early, advanced and complicated lesions regarding Virmani histopathological classification<sup>19</sup>. Next, advanced lesions were divided into regions of FC, shoulders and core using ImageJ software. Lesions with discontinuous fibrous caps were not included in this study.

**Lipid measurements.** Plasma cholesterol and triglycerides were determined by CHOD-PAP kit (Roche/Hitachi) and GPO-PAP kit (Roche/Hitachi) respectively, according to the manufacturer's instructions.

**Cell culture and activation.** Mouse vascular aorta/smooth muscle cells (MOVAS) (ATCC, CRL-2797) were cultured in complete medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (Gibco), 0.2 mg ml<sup>-1</sup> G418 (Invitrogen) and 5 mM sodium pyruvate (Sigma). All cells were maintained in an incubator at 37 °C, 5% CO<sub>2</sub>. To activate MOVAS, cells were cultured in complete medium supplemented with 10 ng ml<sup>-1</sup> recombinant murine PDGF-BB (Peprotech) for 6 h. Subsequently cells were washed to remove the stimulus and maintained with fresh complete medium for 24 h. After this time, supernatants were re-collected, centrifuged (300g, 5 min, 4 °C), and frozen until use. Thioglycollate-elicited macrophages and SVEC4-10 endothelial cells (ATCC) were cultured in complete medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (Gibco). All cell lines were authenticated by ATCC and tested for mycoplasma contaminations.

**Multiplex ELISA of smooth muscle cell supernatants.** Growth factors, cytokines and chemokines were measured in supernatants from activated SMCs using Luminex Multiplex-assays ELISA (Thermo Fisher) according to the manufacturer's instructions.

**Neutrophil isolation.** Human blood neutrophils were isolated from human blood using Polymorphprep (Axi-Shield) following the manufacturer's instructions. Mouse bone-marrow-derived neutrophils were isolated from tibias and femurs from C57BL/6 mice by negative selection using the Neutrophil Isolation Kit (Miltenyi) according to the manufacturer's instructions.

**NET isolation.** Human blood neutrophils ( $2 \times 10^6$ ) were seeded for 30 min and stimulated with 100 nM Phorbol 12-Myristate 13-Acetate (PMA) or 10 ng ml<sup>-1</sup> of human recombinant CCL7 (Peprotech) in HBSS (Life Technologies) supplemented with 5 mM HEPES (Gibco) for 4 h. Next, neutrophils were washed and incubated for 30 min with DMEM containing 10 U ml<sup>-1</sup> of restriction enzyme AluI (New England BioLabs). Supernatants containing the NET fragments were collected and centrifuged (5 min, 300g) to remove remaining cell debris. Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher) was used to measure DNA concentration according to the manufacturer's instructions.

**Cell viability assays.** SMCs were incubated with indicated amounts of isolated NETs, histone H4 (Biomol), or equimolecular amounts of histone H4 fragments (Pepscan). Endothelial cells and macrophages were incubated with 50 µg ml<sup>-1</sup> of histone H4 (Biomol). Cell viability was measured based on PI uptake. PI<sup>+</sup> cells were visualized using a climate chamber fluorescence microscope (Leica, DMi8) and quantified by ImageJ software. In some experiments, SMC viability was measured using Vybrant MTT cell proliferation assay (Thermo Fisher) according to the manufacturer's instructions and measured with a plate reader (Tecan, InfiniteF200Pro). For DNase I treatment, isolated NETs were incubated with DNase I (NE Biolabs) at 10 U ml<sup>-1</sup> for 1 h before addition to SMCs.

Live imaging of cell death was performed on SMCs stained with Calcein AM (Thermo Fisher, 1:1,000). After adding 50 µg ml<sup>-1</sup> of histone H4 or phosphate buffer (control) to the medium, images were acquired every 30 s for 30 min using a climate chamber fluorescence microscope to measure PI and calcein signal. PI influx and calcein efflux was measured using ImageJ software. For live imaging of cell death on atherosclerotic lesions, aortas of HFD-fed *Apoe*<sup>-/-</sup> mice were opened longitudinally and mounted en face on a silicone gel surface. Aortas were incubated with anti-CD31 conjugated to eFluor 450 (Thermo Fisher, 1:50) in combination with Calcein AM (1:1,000) for 1 h. Samples were imaged in z stacks, in intervals of 3 min for a period of 15 min using a LeicaSP5IIMP two-photon laser scanning microscope with a pre-chirped and pulsed Ti:Sapphire Laser (Spectra Physics MaiTai Deepsee) and a 20× NA1.00 (Leica) water dipping objective. Image acquisition and processing were performed using Las software (Leica).

**Inhibition of NET or histone H4 cytotoxicity.** Before the addition to SMCs, NETs (500 ng ml<sup>-1</sup>) were incubated for 1 h with 50 ng ml<sup>-1</sup> of the following antibodies:

Ctrl IgG (Santa Cruz), anti-Myeloperoxidase (Merck), anti-LL37 (Santa Cruz), anti-Neutrophil Elastase (Biorbyt), anti-Cathepsin G (Biorbyt), anti-Proteinase 3 (Santa Cruz), anti-Histone H2A (Cell Signaling Technology), anti-Histone H3 (Abcam), or anti-Histone H4 (Cell Signaling Technology). For inhibition of serine protease activity in NETs, isolated NETs were incubated with 100 nM of Myeloperoxidase Inhibitor-1 (Millipore), Elastase Inhibitor IV (Millipore) or secretory leukocyte protease (SLPI) (R&D systems) for 1 h. For Toll-like receptor inhibition, SMCs were incubated 1 h before NET incubation with 1 µg ml<sup>-1</sup> of TLR1/2, TLR3 and TLR4 inhibitors (Tocris). For inhibition of histone H4 cytotoxicity, recombinant histone H4 was incubated with 100 µg ml<sup>-1</sup> of peptide HIPE for 1 h before addition to SMCs.

**Histone H4-membrane interaction assays.** SMCs were incubated for 5 min at 4 °C to avoid internalization with 50 µg ml<sup>-1</sup> histone H4 or equimolar amounts of biotinylated histone H4 fragments. For inhibition with HIPE, histone H4 was pre-treated with 100 µg ml<sup>-1</sup> HIPE for 1 h before incubating with SMCs. Next, cells were extensively washed and fixed with 2% PFA. Co-cultures of SMCs and neutrophils were stimulated by 100 nM PMA for 2 h. After washing, cells were incubated for another 2 h and then fixed by 2% PFA. Interaction between plasma membranes (lectin) and histone H4 was visualized using confocal microscopy.

**ATP measurement.** SMCs were incubated with 50 µg ml<sup>-1</sup> of recombinant histone H4 for 1 h or 500 ng ml<sup>-1</sup> of isolated NETs for 48 h. Supernatants were centrifuged (5 min, 300g) and extracellular ATP was measured using Cell Titer Glo (Promega) and Tecan plate reader according to the manufacturer's instructions.

**Surface charge alteration and  $\zeta$ -potential measurement.** SMCs were treated for 30 min with 200 µM oleylamine or 200 µM sodium cholesterol sulfate and 1 µM STX64 sulfatase inhibitor (both purchased from Sigma). For cell viability or membrane interaction assays, cells were washed and incubated with 50 µg ml<sup>-1</sup> histone H4 for 1 h at 37 °C or 5 min at 4 °C, respectively. Cell viability or membrane interaction was measured as described above. For  $\zeta$ -potential analysis, SMCs were resuspended in 10 mM sodium chloride and 270 mM sucrose solution. Recombinant histone H4 and BSA (control) were diluted to 0.1 mg ml<sup>-1</sup> in a 16× diluted PBS (Gibco) containing 30 mM sucrose. 100 µl of the sample was injected in the bottom of a disposable folded capillary cell (DTS1070, Malvern), which was prefilled with 600 µl 10 mM NaCl solution. The  $\zeta$  potential was measured at 37 °C using Zetasizer Nano (Malvern).

**Neutrophil extracellular trap analysis.** Neutrophils ( $1 \times 10^5$ ) were seeded and incubated with conditioned media obtained from control- or PDGF-BB-treated SMCs, CCL2 (10 ng ml<sup>-1</sup>) or CCL7 (10 ng ml<sup>-1</sup>) for 4 h. In CCL2 and CCL7 experiments, wells were coated with human recombinant VCAM-1 (1 µg ml<sup>-1</sup>, R&D systems). After washing, neutrophils were fixed with 4% PFA and stained with anti-mouse citrullinated histone H3, anti-mouse Ly6G and DAPI. Immunofluorescence signal was measured with a fluorescent microscope or using a plate reader (Tecan, InfiniteF200Pro).

**Avidin-biotin pull-down of plasma membrane proteins.** SMCs were grown in 10-cm dishes upon 80% confluence. Cells were washed three times with PBS and subsequently incubated with 50 µg ml<sup>-1</sup> H4 (diluted in PBS) or vehicle and incubated for 5 min at 4 °C. Then cells were washed 10 times with ice-cold PBS and subsequently labelled with 250 µg ml<sup>-1</sup> sulfo-NHS-SS-biotin (Pierce) for 30 min on ice. The biotin-labelled cells were incubated with 150 mM glycine solution for 20 min to quench unlabelled free biotin followed by an ice-cold PBS wash. Cells were lysed in PBS Triton (1%) including complete protease inhibitor mixture (Roche), and the lysates were affinity-purified using immobilized NeutrAvidin beads (Thermo Scientific) for 3 h at 4 °C. Finally, the beads were washed with PBS Triton (1%) buffer followed by the addition of SDS-PAGE sample loading buffer and analysed by SDS-PAGE and western blotting using  $\beta$ 1-integrin (antibody generated in the laboratory of R. Fässler, cell surface), H4 and GAPDH (Thermo Fisher, cytosol) antibodies.

**Scanning electron microscopy.** SMCs were incubated with 50 µg ml<sup>-1</sup> of recombinant histone H4 or phosphate buffer for 1 h. Next, cells were washed and the samples were fixed using 4% PFA plus 2.5% glutaraldehyde in PBS (2 h, 4 °C). Cells were then dehydrated by serial 5-min incubations in increasing concentrations of ethanol (30%, 50%, 70%, 80%, 90%, 100%). Samples were dried in an automated critical point dryer (Leica EM CDP 300) and then coated with chromium in a rotary-pumped coating system (Quorum Technologies Q150RS). Imaging was performed at 15 kV with a field emission microscope (JEOL 7600F).

**Neutrophil (trans)-migration.** Migration assays were performed in Zigmond chambers according to the manufacturer. In brief, Ly6G-PE (1A8, BioLegend) labelled neutrophils were seeded (30 min) on a collagen-coated coverslip and mounted on a glass slide chamber. A gradient of PDGF-BB activated SMC vs non-activated SMC supernatants was created and images were acquired over 30 min in 30 s intervals using a climate chamber fluorescence microscope (20× dry objective, Leica, DMi8). Speed and displacement were calculated as previously described<sup>20</sup>.

To analyse transmigration, neutrophils ( $2 \times 10^5$ ) were added to the top compartment of HTS transwell 96 well plates (Corning) with a 3-µm pore size. In the lower

compartment, supernatants obtained from non-activated or PDGF-BB-activated SMCs were added. After incubation for 1 h at 37 °C, transmigrated neutrophils were analysed from the bottom compartment by flow cytometry.

**Analysis of reactive oxygen species.** Bone marrow mouse neutrophils were incubated with 0.1  $\mu$ M H<sub>2</sub>-DCF-DA (Thermo Fisher) in RPMI containing penicillin/streptomycin and 1% FCS for 30 min. After washing, neutrophils were incubated with supernatants from resting or PDGF-BB-activated SMCs for 30 min. Upon oxidation, H<sub>2</sub>-DCF-DA (chemically reduced version of fluorescein), is converted into its fluorescent form thereby acting as an indicator of the amount of reactive oxygen species present. The green fluorescence intensity generated by this dye was measured using flow cytometry.

**Adhesion assay.** Monolayers of SMCs were treated with vehicle or PDGF-BB (24 h, 10 ng ml<sup>-1</sup>). After washing, bone marrow mouse neutrophils stained with Ly6G-APC (1A8) and CD62L-PE (MEL-14) (BioLegend) were added. After incubating for 15 min, cells were washed and fixed with 4% PFA. The number of adhered and polarized (CD62L clustering) neutrophils was analysed by fluorescence microscopy.

**Histone H4-membrane molecular dynamics simulations and blocking peptide design.** The 3D structure of the histone H4 (chain F) was extracted from the X-ray structure of the nucleosome deposited in the Protein Data Bank (PDB code: 1KX5). The histone H4-membrane complex was constructed with assistance from the membrane builder module implemented in the CHARMM-GUI website<sup>21</sup>. Histone H4 was placed around 20 Å above the membrane layer which is composed of 251 DOPC lipids (upper layer) and 50 DOPS/200D DOPC lipids (lower layer). The complex was then solvated by adding water and NaCl to 0.15 M. The water thickness was set to 35 Å from the membrane layer which covers the whole histone H4-membrane complex structure.

The CHARMM36 force field was assigned for the prepared system (solvated histone H4-membrane complex). The complex was subjected to molecular dynamics (MD) simulations by AMBER16. Similar energy minimization and MD simulation protocols as previously described<sup>22</sup> were applied. To relax the system, 2 consecutive steps of energy minimization were used; first 2,500 steps of steepest descent followed by 2,500 steps of conjugate gradient algorithm of energy minimization. During this step the histone H4 and membrane were partially fixed by application of soft position constraint (10 and 2.5 kcal mol<sup>-1</sup> for histone H4 and membrane, respectively). Next, a position-restrained MD phase was carried out for 400 ps by slowly reducing the force constraint applied to constrain the protein (from 10 to 5, 2.5, 0.5, and 0.1 kcal mol<sup>-1</sup>, respectively) and membrane (from 2.5 to 1, 0.5, and 0.1, respectively) atoms. The temperature of the system was continuously increased from 0 to 303.15 K and remained at this temperature by application of Langevin dynamics with a collision frequency of 1 ps<sup>-1</sup>. After this step, free MD simulations were used for 50 ns and then accelerated molecular dynamics (aMD) were carried out from 50 to 200 ns. In these steps (free MD and aMD), the same protocols were applied; temperature and pressure were set and then kept constant at 303.15 K and 1 bar, respectively. A time step was set to 2 fs with application of a SHAKE algorithm. Electrostatic interactions were calculated by use of the particle-mesh Ewald method, and non-bonded interactions were computed by setting the cut-off at 12 Å with the force-based switching at 10 Å.

The histone H4-membrane MD simulations indicated that the N-terminal tail of histone H4 is the first and major part that interacts with the membrane, therefore a blocking peptide was produced against the N-terminal tail. The peptide sequence of histone acetyltransferase that binds and interacts with the N terminus of histone H4 was taken as a starting peptide. Several peptides were designed and the complex conformation of the designed peptides and histone H4 was predicted by protein-protein docking using the HADDOCK2.2 webserver<sup>23</sup>. The derived histone H4-peptide complexes were subjected to structure optimization (energy minimization and short MD simulations) and binding free energy (BFE) calculation to predict the binding strength of the designed peptides with histone H4 by using similar protocols and parameters as in previous studies<sup>22,24</sup>. Molecular mechanics/generalized Born surface area (MM/GBSA) approach using generalized Born model 8 with default parameters was applied to compute binding free energies and only enthalpy values were used to estimate the relative BFE<sup>22</sup>. HIPe-histone H4 complex gave the lowest binding free energy, thus HIPe was chosen for synthesis. The complex between HIPe-histone H4 and membrane was subjected to MD simulation.

**Peptide synthesis.** Peptides used in this study were purchased and synthesized in high purity (>95% HPLC) using solid-phase synthesis (Pepscan). The following peptide sequences were synthesized:

Histone H4, N-terminus, aa1–24: H-SGRKGKGKGLGKGAKRHKVLRD-OH; Histone H4, N-terminus, biotinylated, aa1–24: H-SGRKGKGKGLGKGGAKRHKVLRDK(Biotin)-NH<sub>2</sub>; Histone H4,  $\alpha$ -helix, aa 25–68: H-NIQGITKPAIRRLARRGGVKRISGLIYEETRGVLKFLENVIRD-OH; Histone H4,  $\alpha$ -helix, biotinylated, aa 25–68: H-NIQGITKPAIRRLARRGGVKRISGLIYEETRGVLKFLENVIRKDK(Biotin)-NH<sub>2</sub>; Histone H4, C-terminus, aa

69–102: H-AVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG-OH; Histone H4, C-terminus, biotinylated, aa 69–102: Biotin-Ahx-AVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG-OH; HIPe: H-CEAENEDEDEDSPPEAENEDEDEDSC-OH, S-S bond between Cys at the N- and C-terminus; Scrambled HIPe: H-CDDDPSENEEEEDPNASDEEEC-OH.

**Machine learning screen of histone H4.** Full details of the training and validation of the SVM-based machine learning classifier are described in previous studies<sup>11,25,26</sup>. The classifier is used here to identify membrane-active segments of histone H4. All sub-sequences of length 10–25 amino acids are generated with Python and screened with the classifier.  $\sigma$  scores are tabulated for each peptide alongside other physicochemical characteristics such as net charge and mean hydrophobic moment. Top hits ( $\sigma > 0.8$ ) are sorted by decreasing  $\sigma$  values and cross-referenced with both secondary structure predictions<sup>27</sup> and known secondary structure from crystallographic data (Uniprot ID: P62805). To generate a 'heat map' for segments of H4 that contain a high probability of membrane activity, all 'hit' sub-sequences with  $\sigma > 0$  are aligned with the entire H4 sequence. A normalized net  $\sigma$  score is assigned to each residue, equal to the sum of all  $\sigma$  scores corresponding to peptide 'hits' in which that residue appears, divided by the number of times that amino acid appears in a 'hit'. This ensures that residues are weighted by the magnitude of  $\sigma$ , which is proportional to the likelihood of membrane activity. The subsequence of amino acids that envelop the global maximum (threshold  $\sigma > 0.8$ ) is the most likely membrane-active segment.

To isolate the membrane-active domains of histone H4, we carried out a moving window scan of 10–25 amino acids along the entire 103 amino acid length of the protein (Uniprot ID: P62805) using the membrane activity prediction tool. Out of a total of 1,368 enumerated sequences, 260 were found to have very high  $\sigma$  scores ( $\sigma > 1$ ), and the majority were localized towards the N terminus of H4. Since histone H4 contains several helical domains, we correlated the machine learning results with the known secondary structure of H4. We created a visual heat map to locate the most probable membrane-active domains of H4 based on sequence alignments of sub-sequences and aggregate normalized  $\sigma$  scores. Notably, the top consensus sequence contains the first 24 amino acids of H4 and forms a partial helix with a charge of +8.03 and a hydrophobic moment of 0.247 (SGRGKGGKGLGKGAKRHKVLRD,  $\sigma = 1.266$ ) (Extended Data Fig. 8b).

**Small-angle X-ray scattering.** Small unilamellar vesicles (SUVs) were prepared as previously described<sup>28</sup>. In brief, lyophilized DOPS (sodium salt), DOPE and cholesterol were purchased from Avanti Polar Lipids. Lipids were dissolved in chloroform to 20 mg ml<sup>-1</sup> stock solutions. The following lipid compositions were made: DOPS/DOPE/cholesterol = 20/80/0, 20/75/5, 20/70/10 and 20/60/20. Chloroform was evaporated under nitrogen gas and the lipids were further dried overnight under vacuum. Dried lipids were resuspended in 140 mM NaCl + 10 mM HEPES at pH 7.4 to a final concentration of 20 mg ml<sup>-1</sup>. Aqueous lipid solutions were incubated overnight at 37 °C. SUVs were prepared by sonication of resuspended lipids until clear (3 × 10 min). Monodispersity in size was obtained via extrusion through a 0.2  $\mu$ m filter. The size of the SUVs used in the SAXS experiments is about 200 nm in diameter with a bilayer thickness of around 4 nm, consistent with known studies of lipid bilayers and previous studies of SUVs with dynamic light scattering. The SUVs were stored at 4 °C until use.

Before use, peptides were solubilized in nuclease-free water, mixed together with SUVs in fixed peptide-to-lipid charge ratios and equilibrated at room temperature overnight. Precipitated peptide-lipid complexes were loaded into 1.5 mm glass quartz capillaries and hermetically sealed with an oxygen torch. SAXS experiments were conducted at the Stanford Synchrotron Radiation Lightsource (BL 4-2) with monochromatic X-rays of energy 9 keV. Samples were incubated at 37 °C and centrifuged before measurement. Scattered radiation was collected using a Rayonix-MX225-HE detector (pixel size 73.2  $\mu$ m). The 2D powder diffraction patterns were azimuthally integrated into 1D patterns using the Nika 1.76 package<sup>29</sup> for Igor Pro 7.04 (Wavemetrics) and FIT2D<sup>30</sup>. For all samples, multiple measurements were taken at different times to ensure consistency.

To determine the phases present in each sample, the integrated scattering intensity  $I(q)$  vs.  $q$  was plotted using Mathematica. The  $q$ -measurements corresponding to peak positions were obtained and their ratios were compared to the permitted reflections for different liquid-crystalline lipid phases (for example, lamellar, hexagonal, cubic). Lamellar phases index to integer ratios of 1:2:3 and hexagonal phases index to ratios of  $\sqrt{1:3:4:7:9}$ . Cubic phases observed in our experiments belonged to the *Pn3m* space group, which permits reflections at ratios of  $\sqrt{2:3:4:6:8:9}$ . Measured  $q$  positions for the Bragg peak reflections were fitted to the equation  $q_{\text{measured}} = 2\pi\sqrt{(h^2+k^2+l^2)/a}$ , where  $hkl$  are the Miller indices and  $a$  is the lattice parameter. The curvature-generating ability of the peptides were determined by calculating the lattice parameter  $a$  for the measured cubic phases. The quantity of induced NGC was calculated as the average NGC per unit cell volume using the equation  $\langle K \rangle = 2\pi\chi/A_0a^2$ , where  $\chi$  is the Euler characteristic and  $A_0$  is the surface area per cubic unit cell for each phase. Parameter values are  $\chi = -2$  and  $A_0 = 1.919$  for *Pn3m* cubic phases.

**Atomic force microscopy.** EggPC (Avanti Polar Lipids) was purchased as a solution in chloroform (25 mg ml<sup>-1</sup>). Cholesterol (Avanti Polar Lipids) was purchased as a lyophilized powder of 500 mg. A stock solution was prepared by adding 1 ml of chloroform to 25 mg of cholesterol. All stock solutions were stored at -20 °C.

The lipid bilayers were prepared by fusion of lipid vesicles. SUVs (diameter ≤ 100 nm) containing various compositions of lipids were obtained by the extrusion method. Lipid solutions were prepared in glass tubes using 40 µl of each lipid: EggPC:Cholesterol (80%:20%) (w/w). Chloroform was evaporated under a gas stream and lipids were dried overnight using a vacuum pump. Suspensions of multilamellar vesicles (1 mg ml<sup>-1</sup>) were obtained by resuspending the lipids in 1 ml in 20 mM CaCl<sub>2</sub>, 20 mM NaCl, 20 mM HEPES. Buffers were filtered through 0.22-µm Millipore membranes. The suspensions were vigorously stirred for 3 min. Four freeze-thaw cycles were performed to enhance the engulfment of the buffer inside the vesicles. Afterwards, the suspensions were brought to room temperature, stirred, then extruded using LiposoFast-Basic and LiposoFast-Stabilizer (Avestin) through Nucleopore filters (polycarbonate membranes). The two filter supports and the polycarbonate membranes were soaked in the resuspension buffer whereas the two syringes were carefully washed using the buffer. Each lipid suspension was extruded 5 times using the 200 nm filter and 19 times using the 100 nm filter. The SUVs were characterized by dynamic light scattering (DynaPro NanoStar, Wyatt Technology).

The excess of unbound vesicles was removed by exchanging the solution covering the mica with the deposition buffer (3 times) not containing CaCl<sub>2</sub> using a volume of 20 µl. Histone H4 (1 mg ml<sup>-1</sup>) was diluted in the deposition buffer and deposited onto the mica surface for 15 min except stated otherwise. Loosely bound proteins were gently washed off 3 times by removing 15 µl of the solution and replacing it by the same volume of buffer.

AFM measurements were performed at room temperature in buffer using the peak force-tapping mode with a Multimode 8 and a Nanoscope V controller (Bruker). We used SCAN ASYST-Fluid cantilevers (triangular silicon nitride,  $f_0 = 150$  kHz,  $k = 0.7$  N m<sup>-1</sup> and a 20 nm tip radius, Bruker probes). The imaging parameter was: loading force ranged from 250 to 700 pN, scanning rate of 1 Hz, 512 pixels per line and 512 lines. Each membrane used in our studies was imaged before the addition of any protein to ensure integrity of the membranes.

All images were processed using Gwyddion 2.45 software<sup>31</sup>. When needed, stripe noise was removed with DeStripe<sup>32</sup>. Data were levelled by a mean-plane subtraction, rows were aligned using various methods and for some images few horizontal scars were corrected. The roughness average (arithmetical mean deviation) of the surfaces within the definition area ( $R_a$ ) was calculated using the Statistical Quantities tool of Gwyddion. This value is calculated as the standard deviation of all pixel values from the mean pixel value  $\bar{Z}$ .

**Cell membrane imaging using scanning ion conductance microscopy.** To generate topographic images of the live smooth muscle cell membrane we used scanning ion conductance microscopy (SICM) as previously described<sup>33,34</sup>. SICM is a non-optical method using an electrolyte-filled glass nanopipette as a scanning probe fixed on a three-axis piezo-actuator stage mounted on the Nikon Eclipse Ti inverted fluorescence microscope. The piezo stage is driven by a high-voltage amplifier connected to ICnano scanner controller (Ionscope Ltd). The current in pipette electrode was monitored by Patch clamp EPC 10 (HEKA). Scanning was done with resolution equal to the inner diameter of the pipette which is approximately 50–70 nm. The nanopipettes were made from 1.00 mm outer diameter, 0.58 mm inner diameter borosilicate glass capillaries with inner filament on a laser-based puller P-2000 (both from Sutter Instrument Co.). The measured nanopipette resistance was approximately 100 MΩ. The data acquisition and analysis software are produced by Ionscope. In all experiments, nanopipettes and the bath solution contained the same buffer (144 mM NaCl, 5.4 mM KCl, 1 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub> and 10 mM HEPES, pH = 7.3). All experiments were performed at room temperature.


**Statistics.** Statistical analysis was performed using GraphPad Prism 7 software (GraphPad Software). The ROUT outlier function was used to exclude statistical outliers ( $Q = 1\%$ ). Normal distribution of the data was assessed using the D'Agostino-Pearson omnibus test for normality. Normally distributed data was tested by two-tailed unpaired *t*-test (one variable) or one-way ANOVA with Tukey or Dunnett's correction (>2 variables). When 2 factors were analysed, data was analysed using two-way ANOVA with Tukey's correction. For data that was not normally distributed, the Mann-Whitney test (one variable) or Kruskal-Wallis test with Dunn's correction (>2 variables) was used. In all tests a 95% confidence interval was used, for which  $P < 0.05$  was considered a significant difference. All experiments were replicated at least twice independently. All data are represented as mean ± s.d. Violin Plots were generated by using R.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

## Data availability

The data that support the findings of this study are available from the corresponding authors upon reasonable request.


18. Hasenberg, A. et al. Catchup: a mouse model for imaging-based tracking and modulation of neutrophil granulocytes. *Nat. Methods* **12**, 445–452 (2015).
19. Dzhagalov, I., St John, A. & He, Y. W. The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. *Blood* **109**, 1620–1626 (2007).
20. Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A. & Schwartz, S. M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. *Arterioscler. Thromb. Vasc. Biol.* **20**, 1262–1275 (2000).
21. Gorelik, R. & Gautreau, A. Quantitative and unbiased analysis of directional persistence in cell migration. *Nat. Protoc.* **9**, 1931–1943 (2014).
22. Lee, J. et al. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field. *J. Chem. Theory Comput.* **12**, 405–413 (2016).
23. Wichapong, K. et al. Structure-based design of peptidic inhibitors of the interaction between CC chemokine ligand 5 (CCL5) and human neutrophil peptides 1 (HNP1). *J. Med. Chem.* **59**, 4289–4301 (2016).
24. van Zundert, G. C. P. et al. The HADDOCK2.2 web server: user-friendly integrative modeling of biomolecular complexes. *J. Mol. Biol.* **428**, 720–725 (2016).
25. Alard, J. E. et al. Recruitment of classical monocytes can be inhibited by disturbing heteromers of neutrophil HNP1 and platelet CCL5. *Sci. Transl. Med.* **7**, 317ra196 (2015).
26. Lee, E. Y., Lee, M. W., Fulan, B. M., Ferguson, A. L. & Wong, G. C. L. What can machine learning do for antimicrobial peptides, and what can antimicrobial peptides do for machine learning? *Interface Focus* **7**, 20160153 (2017).
27. Lee, E. Y., Wong, G. C. L. & Ferguson, A. L. Machine learning-enabled discovery and design of membrane-active peptides. *Bioorg. Med. Chem.* **26**, 2708–2718 (2018).
28. McGuffin, L. J., Bryson, K. & Jones, D. T. The PSIPRED protein structure prediction server. *Bioinformatics* **16**, 404–405 (2000).
29. Schmidt, N. W., Mishra, A., Wang, J., DeGrado, W. F. & Wong, G. C. Influenza virus A M2 protein generates negative Gaussian membrane curvature necessary for budding and scission. *J. Am. Chem. Soc.* **135**, 13710–13719 (2013).
30. Ilavsky, J. Nika: software for two-dimensional data reduction. *J. Appl. Crystallogr.* **45**, 324–328 (2012).
31. Hammersley, A. P. FIT2D: a multi-purpose data reduction, analysis and visualization program. *J. Appl. Crystallogr.* **49**, 646–652 (2016).
32. Necas, D. & Klapetek, P. Gwyddion: an open-source software for SPM data analysis. *Cent. Eur. J. Phys.* **10**, 181–188 (2012).
33. Chen, S. W. & Pellequer, J. L. DeStripe: frequency-based algorithm for removing stripe noises from AFM images. *BMC Struct. Biol.* **11**, 7 (2011).
34. Korchev, Y. E. et al. Specialized scanning ion-conductance microscope for imaging of living cells. *J. Microsc.* **188**, 17–23 (1997).



Extended Data Fig. 1 | See next page for caption.

**Extended Data Fig. 1 | Lesional neutrophils do not correlate with macrophage or endothelial phenotype.** **a–f**, Methodology used to analyse advanced atherosclerotic lesions. **a, b**, Representative pictures of H&E staining. **a**, Intima to media ratio was calculated as the quotient of intima area and media area. Red and black dotted lines delineate intima and media, respectively. **b**, Necrotic core area was quantified as the percentage of necrotic core area over the intima area. Red and green dotted lines delineate intima and necrotic core, respectively. **c, d**, Representative pictures of Sirius red staining. **c**, Sirius red pictures were converted into 8-bit images and segmented by thresholding hence generating binary images. Collagen area was quantified as the percentage of collagen area over the intima area. The black dotted line delineates the intima. **d**, Fibrous cap thickness was analysed as the average of lengths measurements in the positions overlapping with the lines of a square-shaped grid. Averaged fibrous cap thickness was corrected by the intima area. **e, f**, Representative


pictures of smooth muscle cell actin (SMA, **e**) and CD68 (**f**) staining. Immunofluorescence images were segmented by thresholding to convert fluorescence signal into a binary image. SMA/CD68 area was quantified as the percentage of SMA/CD68 area over the intima area. The red dotted line delineates the intima. **g–o**, Advanced atherosclerotic lesions were generated in the carotid artery of *Apoe*<sup>-/-</sup> mice. Pearson correlation between lesional neutrophils and lesion size ( $n = 28$  mice, **g**), fibrous cap thickness ( $n = 28$  mice, **h**), collagen area ( $n = 28$  mice, **i**), macrophage area ( $CD68^+, n = 24$  mice, **j**), pro-inflammatory macrophages ( $CD68^+iNOS^+$ ,  $n = 24$  mice, **k**), anti-inflammatory macrophages ( $CD68^+CD206^+$ ,  $n = 23$  mice, **l**), endothelial cell area ( $CD31^+, n = 25$  mice, **m**), VCAM1 expression on endothelial cells ( $n = 25$  mice, **n**) and ICAM1 expression on endothelial cells ( $n = 25$  mice, **o**). Dotted line represents 95% confidence interval. Note that data in **g–i** and **j–o** were generated in a different set of lesions due to a shortage of sections from mice displayed in **g–i**.



Extended Data Fig. 2 | See next page for caption.

**Extended Data Fig. 2 | Modulation of lesional neutrophil counts alters lesion stability.** **a**, Models of neutropenia and neutrophilia. **b, c**, Quantification of lesional neutrophils in indicated treatments.  $n = 79$  sections (ctrl IgG),  $n = 25$  sections (anti-Ly6G),  $n = 27$  sections (PBS),  $n = 58$  sections (AMD3100). Two-sided unpaired *t*-test. **d, e**, Lesion volumes of mice with induced neutropenia (**d**) or induced neutrophilia (**e**).  $n = 10$  mice (ctrl IgG),  $n = 9$  mice (anti-Ly6G),  $n = 15$  mice (PBS),  $n = 14$  mice (AMD3100). Two-sided unpaired *t*-test. **f–h**, Lesion characteristics of mice with antibody-induced neutropenia (anti-Ly6G,  $n = 10$  mice, except in (**g**)  $n = 9$  mice), genetic neutropenia (*Ly6g<sup>cre</sup>Mcl1<sup>flox/flox</sup>*, *Mcl1<sup>ΔN</sup>*,  $n = 16$  mice), induced neutrophilia (AMD3100,  $n = 15$  mice) and genetic neutrophilia (*Lyz2<sup>cre</sup>Cxcr4<sup>flox/flox</sup>*, *Cxcr4<sup>ΔN</sup>*,  $n = 13$  mice) compared with respective controls (isotype IgG ( $n = 10$  mice), *Ly6g<sup>cre</sup>* ( $n = 18$  mice), vehicle ( $n = 15$  mice) or *Lyz2<sup>cre</sup>* ( $n = 11$  mice)), (dashed line). Two-sided unpaired *t*-test; \* $P < 0.05$ ; \*\* $P < 0.01$ . Displayed is the quantification of lesion size (**f**), fibrous cap (FC) thickness (**g**) and collagen area (**h**). **i, j**, Analysis of SMA<sup>+</sup>MYH11<sup>+</sup> (**i**) and SMA<sup>+</sup>MYH11<sup>+</sup> (**j**) SMCs in indicated treatments.  $n = 10$  mice (ctrl IgG),  $n = 9$  mice (anti-Ly6G),  $n = 7$  mice (PBS),  $n = 8$  mice (AMD3100). Two-sided unpaired *t*-test. **k–s**, Antibody-induced neutropenia generates atherosclerotic lesions with


reduced signs of vulnerability in the brachiocephalic artery in *Apoe<sup>-/-</sup>* mice fed a HFD for 16 weeks. **k**, Representative micrographs showing the aortic arch of isotype IgG (ctrl-IgG) and anti-Ly6G-treated mice stained with H&E (top), Sirius red (middle) and antibodies (bottom) to SMA (red), CD68 (green). **l**, Experimental scheme. **m–s**, Analyses of lesion characteristics. Displayed are quantification of intima area (**m**), fibrous cap (FC) thickness (**n**), necrotic core area (**o**), collagen area (**p**), SMC area (SMA<sup>+</sup>, **q**), macrophage area (CD68<sup>+</sup>, **r**), and plaque vulnerability (**s**).  $n = 8$  mice (ctrl IgG),  $n = 9$  mice (anti-Ly6G) except for panel (**m**)  $n = 8$  mice. Two-sided unpaired *t*-test. **t, u**, Proliferating SMCs (Ki67<sup>+</sup>SMA<sup>+</sup>) in lesions of indicated treatments.  $n = 8$  mice (ctrl IgG),  $n = 8$  mice (anti-Ly6G),  $n = 12$  mice (PBS),  $n = 13$  mice (AMD3100). Two-sided unpaired *t*-test. **v, w**, Percentage of SMC area (SMA<sup>+</sup>,  $n = 15$  sections for  $0.51 <$ ,  $n = 25$  sections for  $>0.51$ , **v**) and overall vulnerability ( $n = 10$  sections for  $0.51 <$ ,  $n = 20$  sections  $>0.51$ , **w**) of human atherosclerotic specimens grouped by the number of lesional neutrophils per mm<sup>2</sup>. Two-sided unpaired *t*-test. Data are mean  $\pm$  s.d. BCA, brachiocephalic artery; ctrl, control; SMA, smooth muscle actin; LCA, left carotid artery; LSA, left subclavian artery; MYH11, Myosin heavy chain 11; RCA, right carotid artery.



Extended Data Fig. 3 | See next page for caption.


**Extended Data Fig. 3 | Activated SMCs induce neutrophil chemotaxis and induce NET-mediated SMC death.** **a**, Neutrophil displacement in gradient of supernatant obtained from PDGF-BB-activated or resting SMCs (ctrl).  $n = 20$  neutrophils (ctrl),  $n = 18$  neutrophils (PDGF-BB). Two-way ANOVA.  $P = 1 \times 10^{-15}$  (ctrl vs PDGF-BB). MSD, mean square displacement. **b**, Neutrophils transmigrated towards supernatants obtained from PDGF-BB-activated or resting SMCs (ctrl).  $n = 14$  replicates (ctrl),  $n = 11$  replicates (PDGF-BB). Two-sided unpaired *t*-test. **c, d**, Multiplex ELISA of indicated growth factors and cytokines (**c**) and chemokines (**d**) in cell-free supernatants from SMCs treated with PDGF-BB or vehicle.  $n = 9$  replicates (IL-6, CXCL12),  $n = 10$  replicates (CXCL1, CCL5). Two-sided paired *t*-test. **e**, Pearson correlation between neutrophils and intimal CCL7 in mouse advanced atherosclerotic lesions,  $n = 28$  sections. Dotted line represents 95% confidence interval. **f**, Representative micrographs of mouse atherosclerotic lesions showing SMCs (SMA, green), nuclei (blue), dead cells (TUNEL, red), and NETs (citrullinated histone H3, white). Dashed lines indicate cross-section views. Scale bar, 20  $\mu\text{m}$ . Close-ups represent  $xz$  (left) and  $yz$  (right) cross-sections. Scale bar, 4  $\mu\text{m}$ . Orange arrows indicate points of interactions between dead SMCs and NETs. **g**, Micrographs of mouse atherosclerotic lesions showing SMCs (MYH11, white), nuclei (blue), dead cells (TUNEL, red), and MPO (green). Yellow

arrows indicate points of interactions between dead SMCs and NETs. Asterisks indicate intact MPO<sup>+</sup> cells. **h–j**, Advanced atherosclerotic lesions in the carotid artery were stained with antibodies to Ly6G, CD68, myeloperoxidase (MPO), and citrullinated H3 (citH3) and counterstained with DAPI. **h**, Representative images. Scale bar, 50  $\mu\text{m}$ . **i**, Pie chart showing distribution of macrophage extracellular traps (METs, 1.86%), NETs (80.05%), and extracellular trap DNA (18.09%) based on marker analysis defined underneath,  $n = 35$  sections from 8 mice. **j**, Extracellular trap DNA structures in carotid artery sections from neutropenic mice (anti-Ly6G,  $n = 13$  sections), mice with intact white blood cell count (vehicle treated,  $n = 96$  sections), or neutrophilic mice (AMD3100,  $n = 57$  sections). Two-sided unpaired *t*-test. **k**, Percentage of viable SMCs after exposure to PMA-induced NETs isolated from indicated number of neutrophils.  $n = 16$  biological samples (0,  $2.75 \times 10^6$  neutrophils),  $n = 13$  biological samples ( $0.27510^6$ ,  $0.55 \times 10^6$ ,  $1.375 \times 10^6$ ,  $4.125 \times 10^6$  neutrophils),  $n = 11$  biological samples ( $5.5 \times 10^6$  neutrophils). **l**, Cell death of SMCs incubated with NETs isolated from neutrophils treated with recombinant CCL7.  $n = 67$  fields (−),  $n = 72$  fields (+). Two-sided unpaired *t*-test, \*\*\* $P = 0.000002$ . Data are mean ± s.d. MPO, myeloperoxidase; ND, not detected.




**Extended Data Fig. 4 | Pharmacological and genetic inhibition of NET release reduces traits of atherosclerotic plaque vulnerability.**  
**a**, Experimental scheme. **b–g**, Quantification of lesion characteristics. Displayed are lesion volumes (**b**), lesion size (**c**), fibrous cap (FC) thickness (**d**), necrotic core area (**e**), collagen area (**f**) and macrophage area ( $\text{CD68}^+$ , **g**). Cl-amidine-treated (Cl-a,  $n = 9$  mice) and  $\text{Apoe}^{-/-}\text{Pad4}^{-/-}$  ( $\text{Pad4}^{-/-}$ ,  $n = 8$  mice) are compared to respective controls (PBS,  $n = 8$  mice),  $\text{Apoe}^{-/-}$  ( $\text{Pad4}^{+/+}$ ,  $n = 6$  mice). Two-sided unpaired *t*-tests (PBS vs Cl-a) or two-sided Mann-Whitney tests ( $\text{Pad4}^{+/+}$  vs  $\text{Pad4}^{-/-}$ ) were

used. **h**, Quantification of NETs per section of indicated mice.  $n = 40$  sections (PBS),  $n = 31$  sections (Cl-a),  $n = 35$  sections ( $\text{Apoe}^{-/-}$ ),  $n = 68$  sections ( $\text{Apoe}^{-/-}\text{Pad4}^{-/-}$ ). Two-sided unpaired *t*-test. **i, j**, Analysis of SMA<sup>+</sup>MYH11<sup>+</sup> (**i**) and SMA<sup>-</sup>MYH11<sup>+</sup> (**j**) SMCs in indicated mice. Two-sided unpaired *t*-test (PBS vs Cl-a) or two-sided Mann-Whitney test ( $\text{Pad4}^{+/+}$  vs  $\text{Pad4}^{-/-}$ ) were used. PBS ( $n = 8$  mice), Cl-amidine (Cl-a,  $n = 9$  mice),  $\text{Apoe}^{-/-}$  ( $\text{Pad4}^{+/+}$ ,  $n = 6$  mice),  $\text{Apoe}^{-/-}\text{Pad4}^{-/-}$  ( $\text{Pad4}^{-/-}$ ,  $n = 8$  mice). \* $P < 0.05$ ; \*\* $P < 0.01$ . Data are mean  $\pm$  s.d.




**Extended Data Fig. 5 | NET-derived histone H4 induces cell toxicity.**  
**a–c**, Analysis of cell death (propidium iodide uptake). **a**, NETs were pre-incubated with indicated antibodies for 1 h before addition to SMCs. MPO, myeloperoxidase; NE, neutrophil elastase; CG, cathepsin G; PR3, proteinase 3.  $n = 79$  IgG,  $n = 23$  MPO,  $n = 60$  LL37,  $n = 60$  NE,  $n = 58$  CG and  $n = 60$  PR3 fields. One-way ANOVA with Dunnet's correction.  $P = 0.105$  (MPO),  $P = 0.219$  (LL37),  $P = 0.270$  (NE),  $P = 0.925$  (CG),  $P = 0.999$  (PR3). All conditions were compared against control (ctrl). **b**, NETs were pre-incubated with inhibitors to myeloperoxidase (MPO), neutrophil elastase (NE), or secretory leukocyte protease (SLP) for 1 h before their addition to SMCs.  $n = 96$  ctrl,  $n = 35$  MPO,  $n = 58$  NE,  $n = 58$  SLP fields. One-way ANOVA with Dunnet's correction.  $P = 0.299$  (MPO),  $P = 0.085$  (NE),  $P = 0.978$  (SLP). All conditions were compared against

control (ctrl). **c**, SMCs, endothelial cells (ECs) and peritoneal macrophages (PMs) were incubated with recombinant histone H4. Cell death was assessed by PI uptake.  $n = 36$  and  $n = 36$  for SMCs,  $n = 35$  and  $n = 36$  for ECs,  $n = 47$  and  $n = 39$  for PMs. Two-sided unpaired *t*-test, \* $P = 0.029$ ; \*\* $P = 3.847 \times 10^{-5}$ ; \*\*\* $P = 8.775 \times 10^{-6}$ . **d**, Representative confocal immunofluorescence of advanced atherosclerotic lesions to visualize DNA (DAPI, blue), neutrophils (Ly6G, red), SMCs (SMA, green), histone H4 (magenta), and citrullinated histone H3 (white). Scale bar, 20  $\mu$ m. **e**, Quantification of extranuclear histone H4 per section of indicated treatments.  $n = 17$  ctrl,  $n = 8$  anti-Ly6G,  $n = 9$  AMD3100. One-way ANOVA with Dunnet's correction, \* $P = 0.02$ ; \*\* $P = 0.0002$ . Data are mean  $\pm$  s.d. ctrl, control; SMA, smooth muscle actin.



**Extended Data Fig. 6 | Neutralization of histone H4 stabilizes atherosclerotic lesions.** **a**, Experimental scheme. **b–i**, Quantification of lesion characteristics of the carotid artery. Displayed are lesion volume (**b**), lesion size (**c**), fibrous cap (FC) thickness (**d**), necrotic core area (**e**), collagen area (**f**), macrophage area ( $\text{CD68}^+$ , **g**),  $\text{SMA}^+\text{MYH11}^+$  cells (**h**) and  $\text{SMA}^-\text{MYH11}^+$  cells (**i**).  $n = 14$  mice (ctrl IgG) except for (**h, i**)  $n = 12$  mice.  $n = 11$  mice;  $n = 15$  mice (anti-histone H4) except for (**h, i**)  $n = 12$  mice.


Two-sided unpaired *t*-test. **j–p**, Quantification of lesion characteristics on the brachiocephalic artery. Displayed are lesion size (**j**), fibrous cap (FC) thickness (**k**), necrotic core area (**l**), collagen area (**m**), SMCs ( $\text{SMA}^+$ , **n**), macrophages ( $\text{CD68}^+$ , **o**) and overall vulnerability (**p**). Two-sided unpaired *t*-test,  $n = 12$  mice (ctrl IgG) or 10 mice (anti-histone H4). Data are mean  $\pm$  s.d.



Extended Data Fig. 7 | See next page for caption.

**Extended Data Fig. 7 | NET-derived histone H4 interaction with cell membranes is surface charge dependent and induces a lytic cell death.** **a**, SMCs were pre-incubated with indicated inhibitors before NET treatment. Cell death was assessed by PI uptake.  $n = 24$  fields, except TLR4,  $n = 23$  fields. One-way ANOVA with Dunnet's correction,  $P = 0.729$  (TLR1/2),  $P = 0.999$  (TLR3),  $P = 0.995$  (TLR4). All conditions were compared against control (ctrl). **b**, Representative high-resolution confocal microscopy images were used to visualize cell membrane (lectin, white), histone H4 (magenta) and DNA (DAPI, cyan) in a SMC (S) and neutrophil (N) co-culture. Dashed lines indicate cross-section views represented in Fig. 3j. **c**, Confocal immunofluorescence micrograph to visualize cell membrane (lectin, white), histone H4 (magenta) and DNA (DAPI, cyan). The dashed line indicates the cross-section view represented in Fig. 3k. **d**, **e**, SMCs were incubated with NETs. **d**, Extracellular ATP.  $n = 3$  biological replicates (ctrl),  $n = 6$  biological replicates (NETs). Two-sided Mann–Whitney test. **e**, Flow cytometry analysis of cell size.  $n = 9$  biological replicates. Two-sided unpaired *t*-test. **f**, **g**, SMCs were incubated with histone H4. **f**, Extracellular ATP.  $n = 5$  biological replicates. Two-

sided Mann–Whitney test. **g**, Time-lapse microscopy images were used to measure SMC area before and after incubation with histone H4.  $n = 9$  cells. Two-sided paired *t*-test. **h**, Analysis of the  $\zeta$  potential of SMCs incubated with oleylamine or cholesterol sulfate (chl sulfate).  $n = 9$  biological replicates (ctrl),  $n = 8$  biological replicates (oleylamine),  $n = 6$  biological replicates (chl sulfate). Two-sided Mann–Whitney test. **i**, **j**, SMCs were incubated with recombinant histone H4 after pre-incubation with oleylamine or cholesterol sulfate (chl sulfate). **i**, Confocal microscopy was used to detect histone H4 and plasma cell membrane (phalloidin). Peptide–membrane interaction quantified as the ratio of histone H4-fragment signal and plasma membrane area.  $n = 10$  cells (ctrl),  $n = 20$  cells (histone H4, —),  $n = 20$  cells (oleylamine),  $n = 25$  cells (chl sulfate). One-way ANOVA with Dunnet's correction. \*\* $P = 0.007$ ; \*\*\* $P = 0.0001$  vs ctrl. **j**, Quantification of PI incorporation.  $n = 54$  fields,  $n = 8$  fields,  $n = 10$  fields,  $n = 34$  fields,  $n = 21$  fields and  $n = 19$  fields for each condition represented. One-way ANOVA with Tukey's correction, \* $P = 0.001$ ; \*\* $P = 0.004$ . Data are mean  $\pm$  s.d.




Extended Data Fig. 8 | See next page for caption.

**Extended Data Fig. 8 | Membrane pore-forming activity of histone H4.**

**a**, Scanning electron micrographs of SMCs incubated with recombinant histone H4 or vehicle. **b**, Machine learning screen of full-length sequence histone H4 predicts potent membrane activity at the N terminus (residues 1–24 highlighted in blue). **c**, SAXS data demonstrates that N-terminal domain of histone H4 induces negative Gaussian curvature (NGC) in cell membranes at the indicated peptide:lipid (P/L) ratios. The histone H4 N terminus was incubated with indicated membrane compositions and the resulting structures were measured with SAXS. The peptide induced *Pn3m* cubic phases, which are rich in NGC, and are indicative of membrane permeation. **d**, SMCs were incubated with biotinylated histone H4 fragments (1–24: N terminus; 25–68:  $\alpha$ -helix; 69–102: C terminus). Confocal microscopy was used to detect histone H4 fragments and plasma cell membrane. Peptide–membrane interaction was quantified as the ratio of histone H4 fragment signal and plasma membrane area.  $n = 44$  cells (1–24),  $n = 28$  cells (25–68),  $n = 33$  cells (69–102). One-way ANOVA with Tukey's correction;  $*P = 0.049$ ;  $**P = 4 \times 10^{-14}$ . **e**, PI incorporation in SMCs treated with histone H4 fragments or the full-length protein.

$n = 19$  fields (ctrl),  $n = 24$  fields (histone H4),  $n = 24$  fields (1–24),  $n = 21$  fields (25–68),  $n = 19$  fields (69–102). One-way ANOVA with Dunnett's correction;  $*P = 0.005$ ;  $**P = 0.0001$  vs control. **f**, Histone H4 was pre-incubated with HIPE or vehicle and added to SMCs. Confocal microscopy was used to visualize interaction of histone H4 (green) with plasma cell membrane (phalloidin, red).  $n = 20$  cells (ctrl),  $n = 17$  cells (histone H4),  $n = 15$  cells (histone H4+HIPE). One-way ANOVA with Tukey's correction;  $*P = 9.243 \times 10^{-7}$ ;  $**P = 6.239 \times 10^{-9}$ . Scale bar, 20  $\mu\text{m}$ . **g**, Atomic force microscopy studies of lipid membranes treated with the indicated histone H4:HIPE ratio. Scale bar, 1  $\mu\text{m}$ . Membrane disruption was quantified as membrane roughness.  $n = 13$  membranes (ctrl),  $n = 3$  membranes (1:0),  $n = 3$  (1:1). Kruskal–Wallis test with Dunn's correction. **h**, Live scanning ion conductance microscopy of SMCs. Images represent the plasma membrane before and after incubation with histone H4 and HIPE. **i**, PI incorporation in SMCs treated with recombinant histone H4 in the presence or absence of HIPE.  $n = 33$  fields (ctrl),  $n = 12$  fields (histone H4),  $n = 11$  fields (histone H4 + HIPE). One-way ANOVA with Tukey's correction;  $*P = 0.001$ ;  $**P = 8.844 \times 10^{-6}$ . Data are mean  $\pm$  s.d.



Extended Data Fig. 9 | See next page for caption.

**Extended Data Fig. 9 | Disruption of histone H4–cell membrane interaction prevents pore formation and stabilizes atherosclerotic lesions.** **a**, Experimental scheme. **b–i**, Lesion characteristics in the carotid artery. Displayed are lesion volume (**b**), lesion size (**c**), fibrous cap (FC) thickness (**d**), necrotic core area (**e**), collagen area (**f**), macrophage area (CD68<sup>+</sup>, **g**), SMA<sup>+</sup>MYH11<sup>+</sup> (**h**) and SMA<sup>−</sup>MYH11<sup>+</sup> (**i**) SMCs.  $n = 12$  mice (vehicle),  $n = 11$  mice (HIPe) except for (**h**)  $n = 9$  mice and (**i**)  $n = 10$  mice. Two-sided unpaired *t*-test. **j**, Experimental scheme. **k–q**, Assessment of lesion characteristics. Displayed is quantification lesion size (**k**), fibrous cap (FC) thickness (**l**), necrotic core area (**m**), collagen area (**n**), SMC area (SMA<sup>+</sup>, **o**), macrophage area (**p**) and overall vulnerability (**q**).  $n = 4$  mice (vehicle),  $n = 4$  mice (sHIPe). Two-sided Mann–Whitney test. **r–x**, Assessment of lesion characteristics in the brachiocephalic artery of mice treated as described in **a**. Displayed is quantification lesion size (**r**), fibrous cap (FC) thickness (**s**), necrotic core

area (**t**), collagen area (**u**), SMCs (SMA<sup>+</sup>, **v**), macrophages (CD68<sup>+</sup>, **w**) and overall vulnerability (**x**).  $n = 11$  mice (vehicle),  $n = 11$  mice (HIPe), except for (**s**) Vehicle  $n = 10$ . Two-sided unpaired *t*-test, **y**, Number of lesional neutrophils per section of vehicle- ( $n = 82$  cells) or HIPe- ( $n = 83$  cells) treated mice. Two-sided unpaired *t*-test. **z**, Mice were treated with TNF and received either vehicle control or HIPe. Neutrophils were quantified in the peritoneum (left,  $n = 4$  (vehicle),  $n = 5$  (HIPe)), the bone marrow (middle,  $n = 5$  (vehicle),  $n = 5$  (HIPe)), and the blood (right,  $n = 5$  (vehicle),  $n = 5$  (HIPe)). **aa**, Scheme summarizing the cytotoxic activity of neutrophils during atherosclerotic plaque vulnerability. The interaction of lesional SMCs with neutrophils induces NETosis (1) which acts as a carrier of cytotoxic histone H4 (2). The cationicity of the N-terminal domain of histone H4 induces plasma membrane bending and pore formation leading to SMC lysis (3). SMC death contributes to fibrous cap thinning and increased plaque instability. Data are mean  $\pm$  s.d.

Extended Data Table 1 | Neutrophil counts, weight and lipid levels in mouse experiments

	<b>Neutrophils (x10<sup>6</sup>)</b>	<b>Weight (g)</b>	<b>Cholesterol (mg/dL)</b>	<b>Triglycerides (mg/dL)</b>
<b>ctrl IgG (n=7-10)</b>	0.34±0.14	22.45±0.73	1856.68±372.52	163.27±51.95
<b>Anti-Ly6G (n=7-10)</b>	0.18±0.08	22.64±0.96	1593.50±403.13	149.49±28.73
<b>p-value</b>	0.038	0.716	0.167	0.494
<b>Ly6G<sup>CRE</sup> (n=10)</b>	0.71±0.35	26.40±1.80	1019.20±244.60	142.90±73.30
<b>Ly6G<sup>CRE</sup>Mcl1<sup>flox/flox</sup> (n=8)</b>	0.12±0.05	23.50±1.70	587.80±187.70	187.70±79.30
<b>p-value</b>	0.0002	0.003	0.0008	0.233
<b>PBS (n=15)</b>	0.73±0.32	24.44±2.53	1323.28±488.85	400.12±134.55
<b>AMD3100 (n=15)</b>	1.56±0.58	24.56±2.46	1338.96±460.15	397.30±81.62
<b>p-value</b>	0.00007	0.895	0.931	0.947
<b>Lyz2<sup>CRE</sup> (n=11)</b>	0.609±0.29	25.10±1.80	986.50±107.00	107.20±39.80
<b>Lyz2<sup>CRE</sup>Cxcr4<sup>flox/flox</sup> (n=13)</b>	2.250±0.97	26.50±1.10	1006.20±245.40	111.80±26.70
<b>p-value</b>	0.00002	0.031	0.808	0.741
<b>PBS (n=8)</b>	1.03±0.21	23.75±0.67	2326±220.20	302.40±19.24
<b>Cl-amidine (n=9)</b>	1.19±0.28	23.33±0.78	2575±135.20	241.30±24.38
<b>p-value</b>	0.199	0.696	0.338	0.072
<b>Pad4<sup>+/+</sup> (n=6)</b>	0.67±0.22	28.33±3.39	1357.68±267.15	148.78±63.26
<b>Pad4<sup>-/-</sup> (n=8)</b>	0.72±0.22	25.50±1.60	1583.12±287.77	134.11±37.51
<b>p-value</b>	0.852	0.094	0.215	0.922
<b>ctrl IgG (n=14)</b>	0.64±0.17	25.00±2.32	1064.44±357.92	144.76±57.79
<b>anti-histone H4 (n=15)</b>	0.69±0.27	25.27±1.33	981.43±260.28	144.00±41.94
<b>p-value</b>	0.519	0.781	0.479	0.968
<b>Vehicle (n=12)</b>	0.60±0.36	26.17±2.13	1204.84±433.08	175.05±103.30
<b>HIPe (n=11)</b>	0.41±0.23	28.00±1.18	1313.49±260.41	120.24±36.22
<b>p-value</b>	0.166	0.020	0.479	0.111

Hypercholesterolemic mice were treated as outlined in Extended Data Fig. 2a, Extended Data Fig. 4a, Extended Data Fig. 6a and Extended Data Fig. 9a. Neutrophil count, body weight as well as plasma lipid levels were assessed upon euthanasia. Two-sided unpaired t-test except for *Pad4<sup>+/+</sup>* vs *Pad4<sup>-/-</sup>*, where two-sided Mann–Whitney test was used. All data are presented as mean ± s.d.

# Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

## Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

## Software and code

Policy information about [availability of computer code](#)

### Data collection

FACS DIVA software was used to collect flow cytometry data. Non-fluorescent and immunofluorescence images were taken using Leica Application Suite X v3.4.2.18368 and v3.5.2.18963. xPONENT v4.2 software (Luminex) was used to collect data in Multiplex ELISA experiments. SMC viability using Vybrant MTT cell proliferation assay, NET and ATP analysis was measured using i-Control v1.10 software.  $\zeta$ -potential measurement was performed using Malvern Panalytical v7.11. Scanning electron microscopy images were taken using INCA software (Oxford Instruments). AFM images were acquired using Gwyddion 2.45 software. SICM based cell membrane images were acquired using lonscope software.

### Data analysis

PRISM Graphpad software was used to perform Pearson's correlation, t-tests, Mann-Whitney t-tests and One or two-way ANOVA. Also was used to perform ROUT outlier analysis and D'Agostino-Pearson omnibus test for normality. ProcartaPlex Analyst software (v1.0; Thermo Scientific) was used to analyze Multiplex ELISA experiments. Molecular Dynamics simulations were performed using AMBER16. Protein-protein docking prediction was performed using HADDOCK2.2 webserver. Identification of  $\alpha$ -helical membrane-active sequences was performed using SVM-based machine learning classifier. In SAXS experiments, the 2D powder diffraction patterns were azimuthally integrated into 1D patterns using the Nika 1.76 package15 for Igor Pro 7.04 (Wavemetrics) and FIT2D. Phase analysis in SAXS experiments were performed using Mathematica software. AFM analysis was performed using Gwyddion 2.45 software. IMage J/Fiji software was used to analyze all remaining image data. R was used to visualize violin plots. FlowJo software (BD) was used to analyse flow cytometry data.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](http://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	For animal experiments, statistical power calculation was performed as described in ( <a href="http://www.stat.uiowa.edu/~rlenth/Power/">http://www.stat.uiowa.edu/~rlenth/Power/</a> ) to determine sample size. For in vitro or ex vivo studies, preliminary experiments were performed to determine expected spread of data. Based on this information, the detectable biological difference (30%), and the power (at least 80%), the number of required observations was calculated.
Data exclusions	For animal experiments, animals with carotids showing absence of lesion formation were excluded from the study. The ROUT outlier function was used to exclude statistical outliers ( $Q=1\%$ ). Such exclusion criteria were pre-established.
Replication	All attempts of replication were successful. Independent experiments at different days, with different animal batches or biological sample groups (e.g. blood donors) and complementary methodological strategies (e.g. pharmacologically and genetically-induced manipulations of circulating neutrophil counts) were performed to support our findings.
Randomization	Samples and animals were assigned to groups randomly.
Blinding	For animal experiments, data collection and analysis were performed blinded. For in vitro experiments, data analysis was performed in a computer automated fashion when possible.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	<input type="checkbox"/> Involved in the study <input checked="" type="checkbox"/> Antibodies <input type="checkbox"/> Eukaryotic cell lines <input checked="" type="checkbox"/> Palaeontology <input type="checkbox"/> Animals and other organisms <input checked="" type="checkbox"/> Human research participants <input checked="" type="checkbox"/> Clinical data
-----	---

### Methods

n/a	<input type="checkbox"/> Involved in the study <input checked="" type="checkbox"/> ChIP-seq <input type="checkbox"/> Flow cytometry <input checked="" type="checkbox"/> MRI-based neuroimaging
-----	---

## Antibodies

### Antibodies used

anti-Ly6G (BioXcell, clone 1A8, Cat#BE0075-1, Lot#5291/0614), rat IgG (BioXcell, clone 2A3, Cat#BE0089, Lot#5291/0514), anti-histone H4 (Biorbyt, Polyclonal, Cat#orb225483, Lot#DP3218), rabbit IgG (Dianova, Polyclonal, Cat#011-000-003, Lot#130748), anti-CD45-APCCy7 (Biolegend, clone 30-F11, Cat#103116, Lot#B242535, Dilution 1:200), anti-CD11b-PECy7 (Biolegend, clone M1/70, Cat#101215, Lot#B249268, Dilution 1:200), anti-Ly6G-PerCP Cy5.5 (Biolegend, clone 1A8, Cat#127616, Lot#B248844, Dilution 1:200), anti-Ly6G-PE (Biolegend, clone 1A8, Cat#551461, Lot#4246573, Dilution 1:200), anti-Ly6G-APC (Biolegend, clone 1A8, Cat#127614, Lot#B214302, Dilution 1:200), anti-Ly6C-Fitc (Biolegend, clone Hk1.4, Cat#128006, Lot#B217035, Dilution 1:100), anti-CD115-PE (Thermo Fisher, clone AFS98, Cat#12-1152-83, Lot#1950725, Dilution 1:100), anti-CD62L-PE (Biolegend, clone Hk1.4, Cat#128006, Lot#B208094, Dilution 1:100), anti-Ly6B.2-Alexa 488 (BIORAD, clone 7/4, Cat#MCA771GT, Dilution 1:100)

1:100), anti-CD68 (Abcam, Polyclonal, Cat# ab125212, Lot#GR300628-10, Dilution 1:200), anti-Ly6G (BD Biosciences, clone 1A8, Cat#551459, Lot#7040840, Dilution 1:200), anti-smooth muscle actin-Fitc (Sigma, clone 1A4, Cat#F3777, Lot#038M4865V, dilution 1:500), anti-smooth muscle actin-Cy3 (Sigma, clone 1A4, Cat#C6198, Lot#037M4783V, dilution 1:500), anti-histone H4 (Abcam, Polyclonal, Cat#ab10158, Lot#GR321419-1, dilution 1:100), anti-histone H4-Alexa 488 (Abcam, clone mAbcam 31830, Cat#ab197513, Lot#GR215288-1, dilution 1:100), anti-citrullinated histone H3 (Abcam, Polyclonal, Cat#ab5103, Lot#GR273046-3, dilution 1:100), anti-CD31-Alexa 488 (Biolegend, clone MEC13.3, Cat#102514, Lot#B211217, dilution 1:100), anti-VCAM-1 (R&D, clone 112734, Cat#MAB6432, Lot#EYJ0114081, Dilution 1:100), anti-ICAM-1 (BD Biosciences, clone 3E2, Cat#553250, Lot#2292615, Dilution 1:100), anti-iNOS (Abcam, Polyclonal, Cat#ab15323, dilution 1:100), anti-CD206-Fitc (Biolegend, clone C068C2, Cat#141704, Lot#B213958, Dilution 1:50), anti-Myosin heavy chain 11 (Abcam, Polyclonal, Cat#ab53219, Lot#GR3223026-6, dilution 1:200), anti-Ki67 (Thermo Fisher, clone SP6, Cat#MA5-14520, Lot#TA2514396B, dilution 1:100), anti-CCL7 (Biorbyt, Polyclonal, Cat#orb256344, Lot#B591004, dilution 1:100), anti-CD177 (Abnova, clone 4C4, Cat#H00057126-M01, dilution 1:2000), anti-CD31-eFluor450 (Thermo Fisher, clone 390, Cat#48-0311-80, Lot#4301770, dilution 1:100), anti-myeloperoxidase (Merck Millipore, Polyclonal, Cat#07-496-I, 50 ng/mL), anti-myeloperoxidase (R&D, Polyclonal, Cat#HF3667, Lot#YBZ0318041, dilution 1:100), anti-LL37 (Santa Cruz, Polyclonal, Cat#sc-50423, 50 ng/mL), anti-neutrophil elastase (Biorbyt, Polyclonal, Cat#orb1614, 50 ng/mL), anti-cathepsin G (Biorbyt, Polyclonal, Cat#orb10253, Lot#A1696, 50 ng/mL), anti-proteinase 3 (Santa Cruz, Polyclonal, Cat#sc-74534, Lot#, 50 ng/mL), anti-histone H2A (Cell Signaling, Polyclonal, Cat#25785, Lot#1, 50 ng/mL), anti-histone H3 (Abcam, Polyclonal, Cat#ab1791, Lot#GR3236305-2, 50 ng/mL), anti-histone H4 (Cell Signaling, clone D2X4V, Cat#13919S, Lot#2, 50 ng/mL), rabbit IgG (Santa Cruz, Polyclonal, Cat#sc-74534, Lot#E3013, 50 ng/mL), anti-glyceraldehyde-3-phosphate dehydrogenase (Thermo Fisher, clone GA1R, Cat#MA5-15738-HRP, Lot#, 0.5 µg/mL), anti-rabbit Dylight 550 (Thermo Fisher, Polyclonal, Cat# SA5-10039, Lot#QK2117383, dilution 1:500), anti-rabbit Dylight 650 (Thermo Fisher, Polyclonal, Cat# SA5-10041, Lot#TJ2644634, dilution 1:500), anti-rat Dylight 550 (Thermo Fisher, Polyclonal, Cat# SA5-10027, Lot#RB2150061, dilution 1:500), anti-rat Dylight 650 (Thermo Fisher, Polyclonal, Cat# SA5-10029, Lot#RD2167901, dilution 1:500), anti-rabbit alkaline phosphatase (Immunologic, Polyclonal, Cat#TR-001-AP, dilution 1:500), anti-mouse alkaline poly-horseadish peroxidase (Southern Biotech, Polyclonal, Cat#1090-05, dilution 1:50), anti-rabbit horseadish peroxidase (Thermo Fisher, Polyclonal, Cat#31458, dilution 1:1000).

## Validation

These antibodies are all used for flow cytometry, immunofluorescence or western blot for experiments with mice and human samples. Antibody validations were performed by antibody suppliers per quality assurance literature provided by each supplier

## Eukaryotic cell lines

### Policy information about [cell lines](#)

#### Cell line source(s)

Mouse vascular aorta/smooth muscle cells (MOVAS) (ATCC, CRL-2797™) and SVEC4-10 endothelial cells (ATCC, CRL-2181™) were used in this study.

#### Authentication

All cell lines have been authenticated by ATCC.

#### Mycoplasma contamination

Cell line were tested for mycoplasma contamination and found to be negative.

#### Commonly misidentified lines (See [ICLAC](#) register)

No commonly misidentified cell lines were used.

## Animals and other organisms

### Policy information about [studies involving animals; ARRIVE guidelines](#) recommended for reporting animal research

#### Laboratory animals

8 week old females were used in this study. Apolipoprotein E deficient mice (Apoe-/-) were purchased from Jackson Laboratory. Ly6Gcre (obtained from Matthias Gunzer, Institute for Experimental Immunology and Imaging, University Hospital, University Duisburg-Essen, Essen, Germany) were intercrossed with Apoe-/- and Mcl1flox/flox (obtained from You-Wen He Department of Immunology, Duke University Medical Center, Durham, NC) to generate triple-mutant mice. Pad4-/- (obtained from Kerri Mowen, The Scripps Research Institute, La Jolla, CA, United States) mice were intercrossed with Apoe-/- to generate double-mutant mice. Apoe-/- recipients mice were lethally irradiated and reconstituted with bone marrow obtained from Apoe-/- Lyz2CRECxcr4flox/flox or Apoe-/- to generate mouse chimeras.

#### Wild animals

This study did not involve wild animals.

#### Field-collected samples

This study did not involve samples collected from the field.

#### Ethics oversight

All mouse experiments were performed according to European guidelines for Care and Use of Laboratory Animals. Protocols were approved by the Committee on the Ethics of Animal Experiments of the Academic Medical Center, Amsterdam and Regierung von Oberbayern.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Human research participants

### Policy information about [studies involving human research participants](#)

#### Population characteristics

Carotid Atherosclerotic plaques were collected from all carotid endarterectomy surgeries performed at the Academic Medical Center in Amsterdam between 2008 and 2010. Specimens were collected according to the "Code for Proper Secondary Use of Human Tissue in the Netherlands". This means that all personal information on age, use of medication, all underlying diseases is

not available, and can indeed cause a potential bias.

#### Recruitment

Patients were recruited between 2008 and 2010. All patients that were operated had a >70% stenosis and/or signs of cerebrovascular events (TIA or stroke).

#### Ethics oversight

Informed consent as well as ethical approval are not required, as this is considered 'waste material' and can be used for science according to "Code for Proper Secondary Use of Human Tissue in the Netherlands"

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Flow Cytometry

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

#### Sample preparation

Blood was incubated with red blood cell lysis buffer (150 mM NH4Cl, 10 mM KHCO<sub>3</sub>, 0.1 mM Na2EDTA) for 5 min at room temperature. Leukocytes were stained with antibodies to CD45 (Biolegend, clone: 30-F11), CD11b (Biolegend, clone: M1/70), Ly6G (Biolegend, clone: 1A8), Ly6C (Biolegend, clone: Hk1.4), CD115 (eBioscience, clone: AFS98), Ly6B (BIORAD, clone: 7/4) in staining buffer (20 min, 4 °C).

#### Instrument

Flow cytometry was performed using the LSR Fortessa (Beckton Dickinson)

#### Software

Data was collected using FACS Diva and analysed using FlowJo software (Beckton Dickinson).

#### Cell population abundance

N/A

#### Gating strategy

Gating was based on FSC and SSC area, followed by doublets removal using FSC-H vs FSC-W and SSC-H vs SSC-W. Neutrophils (CD45+ CD11b+ CD115- Ly6Cint Ly6G+) and total monocytes(CD45+ CD11b+ CD115+ Ly6G-). Positive and negative populations were defined by use of a negative control for indicated antibody. In genetic neutropenic mice, neutrophils were gated as (SSChigh CD45+ CD11b+ CD115- Ly6Cint Ly6Bhigh).

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.